<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd"> 
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><?OLF?><?DTDIdentifier.IdentifierValue -//Springer-Verlag//DTD A++ V2.4//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName A++V2.4.dtd?><?SourceDTD.Version 2.4?><?ConverterInfo.XSLTName springer2nlmx2.xsl?><?ConverterInfo.Version 1?><?covid-19-tdm?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Mol Med (Berl)</journal-id><journal-id journal-id-type="iso-abbrev">J. Mol. Med</journal-id><journal-title-group><journal-title>Journal of Molecular Medicine (Berlin, Germany)</journal-title></journal-title-group><issn pub-type="ppub">0946-2716</issn><issn pub-type="epub">1432-1440</issn><publisher><publisher-name>Springer Berlin Heidelberg</publisher-name><publisher-loc>Berlin/Heidelberg</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">7268974</article-id><article-id pub-id-type="publisher-id">1927</article-id><article-id pub-id-type="doi">10.1007/s00109-020-01927-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Novel therapeutic approaches for treatment of COVID-19</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hossein-khannazer</surname><given-names>Nikoo</given-names></name><xref ref-type="aff" rid="Aff1">1</xref><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Shokoohian</surname><given-names>Bahare</given-names></name><xref ref-type="aff" rid="Aff3">3</xref><xref ref-type="aff" rid="Aff4">4</xref></contrib><contrib contrib-type="author"><name><surname>Shpichka</surname><given-names>Anastasia</given-names></name><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref></contrib><contrib contrib-type="author"><name><surname>Aghdaei</surname><given-names>Hamid Asadzadeh</given-names></name><xref ref-type="aff" rid="Aff7">7</xref></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-7773-2435</contrib-id><name><surname>Timashev</surname><given-names>Peter</given-names></name><address><email>timashev.peter@gmail.com</email></address><xref ref-type="aff" rid="Aff5">5</xref><xref ref-type="aff" rid="Aff6">6</xref><xref ref-type="aff" rid="Aff8">8</xref><xref ref-type="aff" rid="Aff9">9</xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Vosough</surname><given-names>Massoud</given-names></name><address><email>masvos@royaninstitute.org</email></address><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="GRID">grid.411600.2</institution-id><institution>Department of Immunology, School of Medicine, </institution><institution>Shahid Beheshti University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.411600.2</institution-id><institution>Gastroenterology and Liver Diseases Research Center, Research Institute for Gastroenterology and Liver Diseases, </institution><institution>Shahid Beheshti University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.417689.5</institution-id><institution>Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, </institution><institution>ACECR, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="GRID">grid.411705.6</institution-id><institution-id institution-id-type="ISNI">0000 0001 0166 0922</institution-id><institution>Department of Medical Biotechnology, School of Advanced Technologies in Medicine, </institution><institution>Tehran University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="GRID">grid.448878.f</institution-id><institution-id institution-id-type="ISNI">0000 0001 2288 8774</institution-id><institution>Institute for Regenerative Medicine, </institution><institution>Sechenov University, </institution></institution-wrap>Moscow, Russia </aff><aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="GRID">grid.14476.30</institution-id><institution-id institution-id-type="ISNI">0000 0001 2342 9668</institution-id><institution>Chemistry Department, </institution><institution>Lomonosov Moscow State University, </institution></institution-wrap>Moscow, Russia </aff><aff id="Aff7"><label>7</label><institution-wrap><institution-id institution-id-type="GRID">grid.411600.2</institution-id><institution>Department of Molecular Biology, Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, </institution><institution>Shahid Beheshti University of Medical Sciences, </institution></institution-wrap>Tehran, Iran </aff><aff id="Aff8"><label>8</label><institution-wrap><institution-id institution-id-type="GRID">grid.424930.8</institution-id><institution-id institution-id-type="ISNI">0000 0004 0637 9621</institution-id><institution>Department of Polymers and Composites, </institution><institution>NN Semenov Institute of Chemical Physics, </institution></institution-wrap>Moscow, Russia </aff><aff id="Aff9"><label>9</label><institution-wrap><institution-id institution-id-type="GRID">grid.4886.2</institution-id><institution-id institution-id-type="ISNI">0000 0001 2192 9124</institution-id><institution>Institute of Photon Technologies, Federal Research Center Crystallography and Photonics RAS, </institution></institution-wrap>Moscow, Russia </aff></contrib-group><pub-date pub-type="epub"><day>3</day><month>6</month><year>2020</year></pub-date><fpage>1</fpage><lpage>15</lpage><history><date date-type="received"><day>15</day><month>4</month><year>2020</year></date><date date-type="rev-recd"><day>11</day><month>5</month><year>2020</year></date><date date-type="accepted"><day>19</day><month>5</month><year>2020</year></date></history><permissions><copyright-statement>&#x000a9; Springer-Verlag GmbH Germany, part of Springer Nature 2020</copyright-statement><license><license-p>This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</license-p></license></permissions><abstract id="Abs1"><p id="Par1">To date, there is no licensed treatment or approved vaccine to combat the coronavirus disease of 2019 (COVID-19), and the number of new cases and mortality multiplies every day. Therefore, it is essential to develop an effective treatment strategy to control the virus spread and prevent the disease. Here, we summarized the therapeutic approaches that are used to treat this infection. Although it seems that antiviral drugs are effective in improving clinical manifestation, there is no definite treatment protocol. Lymphocytopenia, excessive inflammation, and cytokine storm followed by acute respiratory distress syndrome are still unsolved issues causing the severity of this disease. Therefore, immune response modulation and inflammation management can be considered as an essential step. There is no doubt that more studies are required to clarify immunopathogenesis and immune response; however, new therapeutic approaches including mesenchymal stromal cell and immune cell therapy showed inspiring results.</p></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>COVID-19</kwd><kwd>Coronavirus</kwd><kwd>Therapeutic approaches</kwd><kwd>Severe acute respiratory syndrome</kwd><kwd>Acute respiratory distress syndrome</kwd><kwd>Cell therapy</kwd></kwd-group></article-meta></front><body><sec id="Sec1"><title>Introduction</title><p id="Par2">Corona viruses are a large family of enveloped, positive-sense RNA viruses that have the largest RNA genome (rage from 26 to 32 kb) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Several coronavirus epidemics such as Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) have occurred during the past years [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR3">3</xref>]. At the end of 2019, a novel coronavirus infection named coronavirus disease of 2019 (COVID-19) was first identified in Wuhan, China [<xref ref-type="bibr" rid="CR4">4</xref>&#x02013;<xref ref-type="bibr" rid="CR7">7</xref>]. Due to the fast transmission, it is reported in almost all countries and has become a global crisis. Therefore, COVID-19 pandemic becomes an international threat for human health and economy [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR8">8</xref>].</p><p id="Par3">COVID-19 spreads fast among people and the mortality rate is controversial; however, it was less than 2% in some studies. The main manifestations of the disease include fever, dry caught, headache, shortness of breath, pneumonia, acute respiratory distress syndrome (ARDS), septic shock, and even death [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p><p id="Par4">The genome sequencing of this virus revealed more than 82% identity to SARS-CoV [<xref ref-type="bibr" rid="CR9">9</xref>]. Analysis indicated that the binding affinity of virus S protein to the angiotensin-converting enzyme 2 (ACE2) receptor on human alveolar epithelial cells is higher compared with the SARS-CoV [<xref ref-type="bibr" rid="CR10">10</xref>].</p><p id="Par5">Since SARS-CoV-2 is a new pathogen, little is known about it. Moreover, there is no licensed treatment or approved vaccine and the number of new cases and mortality multiplies daily [<xref ref-type="bibr" rid="CR8">8</xref>]. Therefore, it is vital to develop an effective treatment strategy to control the virus spread and prevent the disease [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR11">11</xref>].</p><sec id="Sec2"><title>Immunopathogenesis of COVID-19</title><p id="Par6">Although the pathogenesis of this disease has not been fully understood, it seems that the host immune responses play an important role. Aberrant host immune response causes lung tissue damage, reduced lung capacity, and finally respiratory failure [<xref ref-type="bibr" rid="CR4">4</xref>]. Studies indicated that dendritic cells (DCs) and macrophages are playing crucial role in innate immune responses [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR13">13</xref>]. These cells produce inflammatory cytokines and chemokines including TNF-&#x003b1;, IL-12, IL-6, IFN&#x003b3;, and IL-8, and monocyte chemoattractant protein (MCP-1), macrophage colony-stimulating factor (GM-CSF), and granulocyte-colony-stimulating factor (G-CSF) [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. These inflammatory responses may lead to systemic inflammation [<xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>].</p><p id="Par7">Adoptive immunity plays a major role in viral infections [<xref ref-type="bibr" rid="CR15">15</xref>]. Cytotoxic T cells (CD8+ T cells) are the main T cell subsets that destroy infected cells [<xref ref-type="bibr" rid="CR16">16</xref>]. Therefore, the number of these cells is one of the major factors for clearance of the viral infection [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Preliminarily, it was indicated that the number of total T cells, CD4+ and CD8+ T cells, reduced significantly in COVID-19 patients. This decrease was more intensive in ICU admitted patients compared with that in non-ICU admitted individuals [<xref ref-type="bibr" rid="CR19">19</xref>]. It is also reported that T cell clonal exhaustion occurred during the infection and the expression of certain T cell surface markers like PD1 (programmed cell death protein 1) and TIM-3 (T cell immunoglobulin and mucin domain-containing molecule-3) markedly increased [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. The cytokine storm occurred in response to SARS-CoV-2 infection that led to increased expression of NKG2A (natural-killer group 2, member A) on cytotoxic T cells (CTLs) and NK cells. This upregulation suppressed CTL and NK function and cytokine secretion [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. It is suggested that inflammatory cytokines, TNF-&#x003b1; and IL-6, mainly originated from apoptotic monocytes (CD14+CD16+) and macrophages and induced T CD4+ and T CD8+ cells [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR23">23</xref>]. These excessive inflammatory responses might result in respiratory system pathology and dysfunction [<xref ref-type="bibr" rid="CR23">23</xref>].</p><p id="Par8">Perhaps it takes many years to achieve a specific and effective therapeutic protocol, efficient vaccine, or suitable medicine for the treatment of COVID-19. There is a wide range of existing and current treatment strategies categorized into antiviral drugs, immunotherapy protocols including convalescent serum and monoclonal antibodies, cell-based therapies, hydroxychloroquine, Chinese medicine, and steroids (just for patients who suffer from ARDS) [<xref ref-type="bibr" rid="CR24">24</xref>]. A schematic figure (Fig. <xref rid="Fig1" ref-type="fig">1</xref>) summarized the novel therapeutic approaches in treatment of COVID-19 patients. Moreover, there are a growing number of clinical trials registered for the treatment of COVID-19 (Table <xref rid="Tab1" ref-type="table">1</xref>).<fig id="Fig1"><label>Fig. 1</label><caption><p>Novel therapeutic strategies for treatment of clinical complications of COVID-19. (a) Passive immunotherapy using serum of immunized individuals. (b) Monoclonal antibodies can directly target virus particles. Also, mAbs can be used to eliminate crucial cytokines in progression of inflammation, e.g., IL-6. (c) The effector cells in adoptive immunotherapy can be used to specifically target infected cells and enhance anti-viral immune responses. (d) Mesenchymal stromal cells are key players in immunomodulation of severe immune response. The paracrine effect of these cells can tune down immune reaction. (e) Using nanostructures for drug delivery in different medical applications. (f) Recombinant ACE2 receptor protein in soluble form attaches to viral particles. (g) Antiviral medicines can prohibit viral proliferation</p></caption><graphic xlink:href="109_2020_1927_Fig1_HTML" id="MO1"/></fig></p></sec><sec id="Sec3"><title>Passive immunotherapy</title><sec id="Sec4"><title>Convalescent serum</title><p id="Par9">Antibody injection to the patients and susceptible people provides rapid immunity to treat or prevent the disease [<xref ref-type="bibr" rid="CR25">25</xref>&#x02013;<xref ref-type="bibr" rid="CR27">27</xref>]. Past experiences from SARS and MERS viral infections indicated that passive immunotherapy could be a potential treatment strategy for the patients [<xref ref-type="bibr" rid="CR27">27</xref>&#x02013;<xref ref-type="bibr" rid="CR29">29</xref>]. It is considered that passive immunotherapy could also be beneficial in SARS-CoV-2 infection [<xref ref-type="bibr" rid="CR30">30</xref>]. Extracting neutralizing antibodies from recovered individuals with high titer of antibodies in sera and transfusion to infected patient could deactivate the virus. However, neutralization activity of these antibodies is not fully understood. It has been showed that neutralizing antibodies are not long lasting and only the recently recovered patients are suitable candidates [<xref ref-type="bibr" rid="CR31">31</xref>]. It has also been reported that the neutralizing antibody titers vary among the patients and elderly patients had higher antibody titer compared with young recovered individuals [<xref ref-type="bibr" rid="CR32">32</xref>]. It is supposed that convalescent serum administration may induce phagocytosis and antibody-mediated cellular cytotoxicity [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR27">27</xref>]. One important implications for using convalescent serum is the risk for antibody-dependent enhancement (ADE) [<xref ref-type="bibr" rid="CR33">33</xref>]. It is supposed that these neutralizing antibodies may enhance other viral infections [<xref ref-type="bibr" rid="CR34">34</xref>]. Another major limitation of this strategy is donor shortage. However, by increasing the number of recovered individuals, this limitation would be solved [<xref ref-type="bibr" rid="CR25">25</xref>].</p></sec><sec id="Sec5"><title>Monoclonal antibodies</title><p id="Par10">It has been shown that monoclonal antibodies (mAbs) could be an effective tool for the treatment of viral infectious diseases [<xref ref-type="bibr" rid="CR35">35</xref>&#x02013;<xref ref-type="bibr" rid="CR37">37</xref>]. Different techniques have been used to develop mAbs including phage display library, hybridoma, single B cell isolation, and transgenic mice [<xref ref-type="bibr" rid="CR37">37</xref>]. Various monoclonal antibodies developed against MERS and SARS infections include m396, 80R, and S3.1 against SARS and LCA60 for the treatment of MERS disease [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR37">37</xref>&#x02013;<xref ref-type="bibr" rid="CR41">41</xref>]. These mAbs limited virus replication and facilitated lung recovery in animal models [<xref ref-type="bibr" rid="CR42">42</xref>&#x02013;<xref ref-type="bibr" rid="CR44">44</xref>]. S protein is also the most immunogenic determinant of coronaviruses [<xref ref-type="bibr" rid="CR40">40</xref>]. Several mAbs target receptor-binding domain (RBD) in the virus spike (S) glycoprotein and inhibit the virus to invade the host cell [<xref ref-type="bibr" rid="CR9">9</xref>]. It is reported that mAbs against SARS-CoV-1 could cross react with SARS-CoV-2 [<xref ref-type="bibr" rid="CR45">45</xref>]. It is indicated in the preprint that mAb 1A9 that targets the S protein of SARS-CoV-1 could interact with SARS-CoV-2 [<xref ref-type="bibr" rid="CR46">46</xref>].</p><p id="Par11">Tocilizumab is a humanized monoclonal antibody against IL-6 receptor cytokine. Tocilizumab targets both membrane and soluble-bound IL-6 receptors. This mAb is used for the treatment of COVID-19 patients [<xref ref-type="bibr" rid="CR47">47</xref>]. It is shown that the IL-6 level is considerably high in severe COVID-19 cases. Treatment of 21 severe COVID-19 cases with tocilizumab indicated that using this monoclonal antibody is an effective treatment and well tolerated in these patients. In the preprinted study, tocilizumab caused body temperature and CRP returned to the normal levels and improved lung function [<xref ref-type="bibr" rid="CR48">48</xref>]. There are also many registered clinical trials on efficiency and safety of tocilizumab for the treatment of COVID-19 (Table <xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Variety of therapeutic agents used in clinical trials registered to treat COVID-19</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Group</th><th rowspan="2">Therapeutic agent</th><th colspan="4">Example of clinical trials registered at <ext-link ext-link-type="uri" xlink:href="http://clinicaltrials.gov">ClinicalTrials.gov</ext-link></th></tr><tr><th>CT number</th><th>Country</th><th>Recruitment status</th><th>Phase</th></tr></thead><tbody><tr><td rowspan="8">Serum</td><td>Convalescent serum</td><td>NCT04327349</td><td>Iran</td><td>Enrolling by invitation</td><td>Phase I</td></tr><tr><td rowspan="4">Convalescent plasma</td><td>NCT04372979</td><td>France</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td>NCT04343755</td><td>USA</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>NCT04363034</td><td>USA</td><td>Available</td><td>NA</td></tr><tr><td>NCT04333355</td><td>Mexico</td><td>Recruiting</td><td>Phase I</td></tr><tr><td>Inactivated convalescent plasma</td><td>NCT04292340</td><td>China</td><td>Recruiting</td><td>Phase I</td></tr><tr><td>Immunoglobulin of cured patients</td><td>NCT04264858</td><td>China</td><td>Not yet recruiting</td><td>NA</td></tr><tr><td>Immunoglobulins obtained with DFPP</td><td>NCT04346589</td><td>Italy</td><td>Recruiting</td><td>NA</td></tr><tr><td rowspan="30">Monoclonal antibodies</td><td rowspan="5">Tocilizumab</td><td>NCT04322773</td><td>Denmark</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>NCT04317092</td><td>Italy</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>NCT04331795</td><td>USA</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>NCT04377659</td><td>USA</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>NCT04345445</td><td>Malaysia</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td rowspan="2">Sarilumab</td><td>NCT04315298</td><td>USA</td><td>Recruiting</td><td>Phase II/III</td></tr><tr><td>NCT04324073</td><td>France</td><td>Recruiting</td><td>Phase II/III</td></tr><tr><td>Avdoralimab</td><td>NCT04371367</td><td>France</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>Gimsilumab</td><td>NCT04351243</td><td>USA</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>Siltuximab</td><td>NCT04329650</td><td>Spain</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>Bevacizumab</td><td>NCT04275414</td><td>China</td><td>Recruiting</td><td>Phase II/III</td></tr><tr><td>Eculizumab</td><td>NCT04288713</td><td>USA</td><td>Available</td><td>Phase I</td></tr><tr><td>Emapalumab</td><td>NCT04324021</td><td>Sweden</td><td>Recruiting</td><td>Phase II/III</td></tr><tr><td>Clazakizumab</td><td>NCT04381052</td><td>USA</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td rowspan="2">Canakinumab</td><td>NCT04362813</td><td>USA, Spain, UK</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>NCT04348448</td><td>Italy</td><td>Not yet recruiting</td><td>NA</td></tr><tr><td>Olokizumab</td><td>NCT04380519</td><td>Russia</td><td>Recruiting</td><td>Phase II/III</td></tr><tr><td>Otilimab</td><td>NCT04376684</td><td>UK</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td>Sirukumab</td><td>NCT04380961</td><td>USA</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>Emapalumab</td><td>NCT04324021</td><td>Sweden</td><td>Recruiting</td><td>Phase II/III</td></tr><tr><td>Lenzilumab</td><td>NCT04351152</td><td>USA</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>Leronlimab</td><td>NCT04343651</td><td>USA</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>Ravulizumab</td><td>NCT04369469</td><td>USA</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td>Nivolumab</td><td>NCT04343144</td><td>France</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Meplazumab</td><td>NCT04275245</td><td>China</td><td>Recruiting</td><td>Phase I/II</td></tr><tr><td>CD24Fc</td><td>NCT04317040</td><td>USA</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td>TJ003234</td><td>NCT04341116</td><td>USA</td><td>Recruiting</td><td>Phase I/II</td></tr><tr><td>IC14</td><td>NCT04346277</td><td>Italy</td><td>Available</td><td>NA</td></tr><tr><td>Anakinra</td><td>NCT04362111</td><td>UK</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td>Anakinra vs. siltuximab vs. tocilizumab</td><td>NCT04330638</td><td>Belgium</td><td>Recruiting</td><td>Phase III</td></tr><tr><td rowspan="6">Interferons</td><td>IFN-&#x003b1;</td><td>NTC04320236</td><td>China</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>Interferon beta-1A</td><td>NCT04350671</td><td>Iran</td><td>Enrolling by invitation</td><td>Phase IV</td></tr><tr><td>Recombinant human interferon &#x003b1;1&#x003b2;</td><td>NCT04293887</td><td>China</td><td>Not yet recruiting</td><td>Early Phase I</td></tr><tr><td>Recombinant human interferon alpha-1b</td><td>NCT04320238</td><td>China</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>Peginterferon lambda-1a</td><td>NCT04331899</td><td>USA</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>Pegylated interferon lambda</td><td>NCT04343976</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td rowspan="5">NK cells</td><td rowspan="2">NK cells</td><td>NCT04280224</td><td>China</td><td>Recruiting</td><td>Phase I</td></tr><tr><td>NCT04344548</td><td>Colombia</td><td>Not yet recruiting</td><td>Phase I/II</td></tr><tr><td>iPSC-derived NK cells</td><td>NCT04324996</td><td>USA</td><td>Not yet recruiting</td><td>Phase I</td></tr><tr><td>IL15-NK cells vs. NKG2D CAR-NK cells vs. ACE2 CAR-NK cells vs. NKG2D-ACE2 CAR-NK cells</td><td>NCT04324996</td><td>China</td><td>Recruiting</td><td>Phase I/II</td></tr><tr><td>CYNK-001</td><td>NCT04365101</td><td>USA</td><td>Not yet recruiting</td><td>Phase I/II</td></tr><tr><td rowspan="15">Kinase inhibitors</td><td rowspan="5">Ruxolitinib</td><td>NCT04362137</td><td>UK</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>NCT04348071</td><td>USA</td><td>Not yet recruiting</td><td>Phase II/III</td></tr><tr><td>NCT04355793</td><td>USA</td><td>Available</td><td>NA</td></tr><tr><td>NCT04354714</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>NCT04377620</td><td>USA</td><td>Recruiting</td><td>Phase III</td></tr><tr><td rowspan="3">Baricitinib</td><td>NCT04340232</td><td>USA</td><td>Not yet recruiting</td><td>Phase II/III</td></tr><tr><td>NCT04358614</td><td>Italy</td><td>Completed</td><td>Phase II/III</td></tr><tr><td>NCT04346147</td><td>Spain</td><td>Recruiting</td><td>Phase II</td></tr><tr><td rowspan="2">Acalabrutinib</td><td>NCT04346199</td><td>Spain</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>NCT04380688</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Duvelisib</td><td>NCT04372602</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Tofacitinib</td><td>NCT04332042</td><td>Italy</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Imatinib</td><td>NCT04346147</td><td>Spain</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>Ibrutinib</td><td>NCT04375397</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Nintedanib</td><td>NCT04338802</td><td>China</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td rowspan="5">Other immunosuppressors</td><td>Fingolimod</td><td>NCT04280588</td><td>China</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>Sirolimus</td><td>NCT04341675</td><td>USA</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>Tacrolimus</td><td>NCT04341038</td><td>Spain</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>Lenalidomide</td><td>NCT04361643</td><td>Spain</td><td>Not yet recruiting</td><td>Phase IV</td></tr><tr><td>Methotrexate</td><td>NCT04352465</td><td>Brazil</td><td>Not yet recruiting</td><td>Phase I/II</td></tr><tr><td rowspan="24">Antivirals</td><td rowspan="3">Remdesivir</td><td>NCT04292899</td><td>USA</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>NCT04280705</td><td>USA</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>NCT04365725</td><td>France</td><td>Available</td><td>NA</td></tr><tr><td rowspan="3">Favipiravir</td><td>NCT04336904</td><td>Italy</td><td>Active, not recruiting</td><td>Phase III</td></tr><tr><td>NCT04346628</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>NCT04349241</td><td>Egypt</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td>Umifenovir</td><td>NCT04350684</td><td>Iran</td><td>Enrolling by invitation</td><td>Phase IV</td></tr><tr><td>Abidol hydrochloride vs. oseltamivir vs. lopinavir/ritonavir</td><td>NCT04255017</td><td>China</td><td>Recruiting</td><td>Phase IV</td></tr><tr><td rowspan="4">Lopinavir/ritonavir</td><td>NCT04330690</td><td>Canada</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>NCT04307693</td><td>Korea</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>NCT04346147</td><td>Spain</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>NCT04328285</td><td>France</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>Galidesivir</td><td>NCT03891420</td><td>Brazil</td><td>Recruiting</td><td>Phase I</td></tr><tr><td>Danoprevir, ritonavir</td><td>NCT04345276</td><td>China</td><td>Recruiting</td><td>Phase IV</td></tr><tr><td>Darunavir/cobicistat</td><td>NCT04252274</td><td>China</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>Virazole</td><td>NCT04356677</td><td>USA</td><td>Not yet recruiting</td><td>Phase I</td></tr><tr><td>Clevudine</td><td>NCT04347915</td><td>Korea</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td rowspan="2">Nitazoxanide</td><td>NCT04348409</td><td>Brazil</td><td>Recruiting</td><td>NA</td></tr><tr><td>NCT04359680</td><td>USA</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td rowspan="5">Hydroxychloroquine</td><td>NCT04329611</td><td>Canada</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>NCT04323631</td><td>Israel</td><td>Not yet recruiting</td><td>Early Phase I</td></tr><tr><td>NCT04340544</td><td>Germany</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td>NCT04345692</td><td>USA</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>NCT04362332</td><td>Netherlands</td><td>Recruiting</td><td>Phase IV</td></tr><tr><td rowspan="3">Antibiotics</td><td>Azithromycin</td><td>NCT04332107</td><td>USA</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td>Doxycycline</td><td>NCT04371952</td><td>France</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td>Carrimycin</td><td>NCT04286503</td><td>China</td><td>Not yet recruiting</td><td>Phase IV</td></tr><tr><td rowspan="7">Decoy biomolecules</td><td rowspan="2">rhACE2, rhACE2</td><td>NCT04287686</td><td>China</td><td>Withdrawn</td><td>NA</td></tr><tr><td>NCT04335136</td><td>Austria, Denmark, Germany</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>rbACE2</td><td>NCT04375046</td><td>Egypt</td><td>Not yet recruiting</td><td>Phase I</td></tr><tr><td rowspan="2">PUL-042, PUL-042</td><td>NCT04313023</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>NCT04312997</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Rhu-pGSN</td><td>NCT04358406</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Piclidenoson</td><td>NCT04333472</td><td>Israel</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td rowspan="5">ACE inhibitors and AR blockers</td><td>Ramipril</td><td>NCT04366050</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Valsartan</td><td>NCT04335786</td><td>Netherlands</td><td>Recruiting</td><td>Phase IV</td></tr><tr><td>Losartan</td><td>NCT04335123</td><td>USA</td><td>Recruiting</td><td>Phase I</td></tr><tr><td rowspan="2">Telmisartan</td><td>NCT04355936</td><td>Argentina</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>NCT04360551</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td rowspan="19">MSC and other cells</td><td>Cardiosphere-derived cells</td><td>NCT04338347</td><td>USA</td><td>Available</td><td>NA</td></tr><tr><td>Dental pulp mesenchymal stem cells</td><td>NCT04302519</td><td>China</td><td>Not yet recruiting</td><td>Phase I</td></tr><tr><td>Dental pulp stem cells</td><td>NCT04336254</td><td>China</td><td>Recruiting</td><td>Phase I/II</td></tr><tr><td>MSC exosomes</td><td>NCT04276987</td><td>China</td><td>Not yet recruiting</td><td>Phase I</td></tr><tr><td rowspan="3">MSC</td><td>NCT04252118</td><td>China</td><td>Recruiting</td><td>Phase I</td></tr><tr><td>NCT04361942</td><td>Spain</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>NCT04377334</td><td>Germany</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td rowspan="3">AD MSC</td><td>NCT04362189</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>NCT04352803</td><td>USA</td><td>Not yet recruiting</td><td>Phase I</td></tr><tr><td>NCT04366323</td><td>Spain</td><td>Not yet recruiting</td><td>Phase I/II</td></tr><tr><td rowspan="2">BM-MSC</td><td>NCT04346368</td><td>China</td><td>Not yet recruiting</td><td>Phase I/II</td></tr><tr><td>NCT04345601</td><td>USA</td><td>Not yet recruiting</td><td>Early Phase I</td></tr><tr><td rowspan="6">UC-MSC</td><td>NCT04355728</td><td>USA</td><td>Recruiting</td><td>Phase I/II</td></tr><tr><td>NCT04273646</td><td>China</td><td>Not yet recruiting</td><td>NA</td></tr><tr><td>NCT04333368</td><td>France</td><td>Recruiting</td><td>Phase I/II</td></tr><tr><td>NCT04269525</td><td>China</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>NCT04339660</td><td>China</td><td>Recruiting</td><td>Phase I/II</td></tr><tr><td>NCT04366271</td><td>Spain</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>WJ-MSC</td><td>NCT04313322</td><td>Jordan</td><td>Recruiting</td><td>Phase I</td></tr><tr><td rowspan="10">Corticosteroids</td><td rowspan="2">Ciclesonide</td><td>NCT04330586</td><td>Korea</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>NCT04381364</td><td>Sweden</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Budesonide</td><td>NCT04355637</td><td>Spain</td><td>Recruiting</td><td>Phase IV</td></tr><tr><td rowspan="2">Dexamethasone</td><td>NCT04325061</td><td>Spain</td><td>Not yet recruiting</td><td>Phase IV</td></tr><tr><td>NCT04360876</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Prednisone</td><td>NCT04344288</td><td>France</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>Prednisone vs. hydrocortisone</td><td>NCT04359511</td><td>France</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td rowspan="2">Methylprednisolone</td><td>NCT04273321</td><td>China</td><td>Suspended</td><td>NA</td></tr><tr><td>NCT04274071</td><td>USA</td><td>Completed</td><td>NA</td></tr><tr><td>Methylprednisolone sodium succinate</td><td>NCT04343729</td><td>Brazil</td><td>Recruiting</td><td>Phase II</td></tr><tr><td rowspan="6">Sedatives, antidepressants, neuroleptics</td><td rowspan="2">Chlorpromazine</td><td>NCT04366739</td><td>France</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td>NCT04354805</td><td>Egypt</td><td>Not yet recruiting</td><td>Phase I/II</td></tr><tr><td>Thalidomide</td><td>NCT04273529</td><td>China</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Fluvoxamine</td><td>NCT04342663</td><td>USA</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>Fluoxetine</td><td>NCT04377308</td><td>USA</td><td>Recruiting</td><td>Phase IV</td></tr><tr><td>Dexmedetomidine</td><td>NCT04358627</td><td>Spain</td><td>Not yet recruiting</td><td>NA</td></tr><tr><td rowspan="30">Others</td><td>Azoximer bromide</td><td>NCT0438177</td><td>Russia</td><td>Recruiting</td><td>Phase II/III</td></tr><tr><td>Etoposide</td><td>NCT04356690</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Bicalutamide</td><td>NCT04374279</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Selinexor</td><td>NCT04349098</td><td>USA</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>Melphalan</td><td>NCT04380376</td><td>Russia</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>Bromhexine</td><td>NCT04355026</td><td>Slovenia</td><td>Recruiting</td><td>Phase IV</td></tr><tr><td><italic>N</italic>-acetylcysteine</td><td>NCT04374461</td><td>USA</td><td>Recruiting</td><td>Phase IV</td></tr><tr><td>Sargramostim</td><td>NCT04326920</td><td>Belgium</td><td>Recruiting</td><td>Phase IV</td></tr><tr><td>Angiotensin peptide (1-7) derived plasma</td><td>NCT04375124</td><td>Turkey</td><td>Recruiting</td><td>NA</td></tr><tr><td>Defibrotide</td><td>NCT04335201</td><td>Italy</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Aviptadil</td><td>NCT04311697</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Dornase alpha</td><td>NCT04355364</td><td>France</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>Nafamostat mesilate</td><td>NCT04352400</td><td>Italy</td><td>Not yet recruiting</td><td>Phase II/III</td></tr><tr><td rowspan="2">Camostat mesilate</td><td>NCT04321096</td><td>Denmark</td><td>Not yet recruiting</td><td>Phase I/II</td></tr><tr><td>NCT04353284</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>Almitrine</td><td>NCT04357457</td><td>France</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td>Sildenafil citrate</td><td>NCT04304313</td><td>China</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>Progesterone</td><td>NCT04365127</td><td>USA</td><td>Recruiting</td><td>Phase I</td></tr><tr><td rowspan="2">Colchicine</td><td>NCT04375202</td><td>Italy</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>NCT04355143</td><td>USA</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>Tetrandrine</td><td>NCT04308317</td><td>China</td><td>Enrolling by invitation</td><td>Phase IV</td></tr><tr><td>Vazegepant</td><td>NCT04346615</td><td>USA</td><td>Recruiting</td><td>Phase II/III</td></tr><tr><td>Dapagliflozin</td><td>NCT04350593</td><td>USA</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>Isotretinoin</td><td>NCT04361422</td><td>Egypt</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td>Deferoxamine</td><td>NCT04333550</td><td>Iran</td><td>Recruiting</td><td>Phase I/II</td></tr><tr><td>SnPP protoporphyrin</td><td>NCT04371822</td><td>Egypt</td><td>Not yet recruiting</td><td>Phase I</td></tr><tr><td>Ascorbic acid</td><td>NCT04363216</td><td>USA</td><td>Not yet recruiting</td><td>Phase II</td></tr><tr><td>BACTEK-R</td><td>NCT04363814</td><td>Spain</td><td>Not yet Recruiting</td><td>Phase III</td></tr><tr><td>Traditional Chinese medicine</td><td>NCT04323332</td><td>China</td><td>Not yet recruiting</td><td>Phase III</td></tr><tr><td>Huaier granule</td><td>NCT04291053</td><td>China</td><td>Not yet recruiting</td><td>Phase II/III</td></tr><tr><td rowspan="13">Combined</td><td rowspan="2">Favipiravir, hydroxychloroquine</td><td>NCT04359615</td><td>Iran</td><td>Not yet recruiting</td><td>Phase IV</td></tr><tr><td>NCT04376814</td><td>Iran</td><td>Enrolling by invitation</td><td>NA</td></tr><tr><td>Favipiravir, tocilizumab</td><td>NCT04310228</td><td>China</td><td>Recruiting</td><td>NA</td></tr><tr><td rowspan="3">Hydroxychloroquine, azithromycin</td><td><ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/show/NCT04328272">NCT04328272</ext-link></td><td>Pakistan</td><td>Not yet Recruiting</td><td>Phase III</td></tr><tr><td>NCT04329832</td><td>USA</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>NCT04359316</td><td>Iran</td><td>Not yet recruiting</td><td>Phase IV</td></tr><tr><td>Hydroxychloroquine, nitazoxanide</td><td>NCT04361318</td><td>Egypt</td><td>Not yet recruiting</td><td>Phase II/III</td></tr><tr><td>Hydroxychloroquine, azithromycin, tocilizumab</td><td>NCT04332094</td><td>Spain</td><td>Recruiting</td><td>Phase II</td></tr><tr><td>Hydroxychloroquine vs. hydroxychloroquine, lopinavir/ritonavir vs. hydroxychloroquine, azithromycin</td><td>NCT04359095</td><td>Colombia</td><td>Not yet recruiting</td><td>Phase II/III</td></tr><tr><td>Hydroxychloroquine, famotidine</td><td>NCT04370262</td><td>USA</td><td>Recruiting</td><td>Phase III</td></tr><tr><td>Ivermectin, Nitazoxanide</td><td>NCT04360356</td><td>Egypt</td><td>Not yet recruiting</td><td>Phase II/III</td></tr><tr><td>Lopinavir/ritonavir, ribavirin, interferon beta-1B</td><td>NCT04276688</td><td>China</td><td>Completed</td><td>Phase II</td></tr><tr><td>Met-enkephalin, tridecactide</td><td>NCT04374032</td><td>Bosnia and Herzegovina</td><td>Recruiting</td><td>Phase II/III</td></tr></tbody></table><table-wrap-foot><p><italic>ACE</italic> angiotensin-converting enzyme; <italic>AR</italic> angiotensin receptor; <italic>DFPP</italic> double-filtration plasmapheresis; <italic>MSC</italic> mesenchymal stem (stromal) cells; <italic>AD MSC</italic> adipose-derived MSC; <italic>BM-MSC</italic> bone marrow&#x02013;derived MSC; <italic>UC-MSC</italic> umbilical cord&#x02013;derived MSC; <italic>WJ-MSC</italic> Wharton jelly&#x02013;derived MSC; <italic>NK cells</italic> natural killer cells; <italic>rhACE2</italic> recombinant human angiotensin-converting enzyme 2; <italic>rbACE2</italic> recombinant bacterial angiotensin-converting enzyme 2; <italic>Rhu-pGSN</italic> recombinant human plasma gelsolin</p></table-wrap-foot></table-wrap></p><p id="Par12">VEGF is one of the main mediators of vascular permeability and progression of ARDS. Bevacizumab is a humanized monoclonal antibody that targets VEGF and employed in a phase II/III clinical trial for the treatment of COVID-19 patients (NCT04275414).</p><p id="Par13">As described earlier, during the SARS-CoV-2 infection, exhaustion of T and NK cells happens. In order to restore these cells, using monoclonal antibodies to block the PD-1/PD-L1 and TIM3 pathways may have beneficial therapeutic effects as well [<xref ref-type="bibr" rid="CR49">49</xref>].</p></sec></sec><sec id="Sec6"><title>Kinase inhibitors</title><p id="Par14">It is suggested that an inhibitor of Janus kinase (JAK) called baricitinib could prevent the entry of SARS-CoV-2 into the host cells and also inhibit the inflammation [<xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. Cyclin G-associated kinase (GAK) and AP2-associated protein kinase 1 (AAK1) are endocytosis regulators. Baricitinib might inhibit SARS COV-2 entry by disruption of these regulators. Other JAK inhibitors such as fedratinib and ruxolitinib are also candidates for decreasing inflammatory cytokines in COVID-19 individuals [<xref ref-type="bibr" rid="CR51">51</xref>]. Although JAK inhibitors have wide effects and can inhibit cytokine secretion such as IFN-&#x003b1;, more studies need to confirm their safety and efficiency [<xref ref-type="bibr" rid="CR14">14</xref>].</p></sec><sec id="Sec7"><title>Adoptive immunotherapy</title><p id="Par15">Adoptive transfer of antigen-specific T cells has been developed for the treatment of cancers, autoimmunity, and viral infections including hepatitis B virus (HBV), hepatitis C virus (HCV), and cytomegalovirus (CMV) [<xref ref-type="bibr" rid="CR24">24</xref>&#x02013;<xref ref-type="bibr" rid="CR26">26</xref>]. In this approach, anti-viral-specific T cell clones are generated, expanded, and purified in vitro [<xref ref-type="bibr" rid="CR26">26</xref>]. It is shown that engineered SARS-specific CD8+ T cells had normal activity and function and may be a potential therapeutic tool for SARS infection [<xref ref-type="bibr" rid="CR27">27</xref>]. Recently, it has been indicated that the number of CD8+ T cells decreased dramatically and the ratio of CD4+/CD8+ T cells increased during the SARS-CoV-2 infection. This decrease in the number of CD8+ lymphocytes has been correlated with the disease severity and clinical outcome [<xref ref-type="bibr" rid="CR52">52</xref>]. It has also indicated that CD8+ T cells and the CD4+/CD8+ ratio decreased and increased respectively after the treatment. It seems that CD8+ T cells play an important role in COVID-19 and could be a potential biomarker of the disease [<xref ref-type="bibr" rid="CR52">52</xref>, <xref ref-type="bibr" rid="CR53">53</xref>]. Due to these findings, adoptive transfer of COVID-19-specific CD8+ T cells may be an effective treatment strategy [<xref ref-type="bibr" rid="CR28">28</xref>]. NK cells are innate immune cells that play a crucial role in host immune response after viral infections [<xref ref-type="bibr" rid="CR54">54</xref>]. Preprinted studies indicated that NK cell population decreased remarkably during the disease [<xref ref-type="bibr" rid="CR55">55</xref>, <xref ref-type="bibr" rid="CR56">56</xref>]. It has been indicated that during SARS-CoV-2 infection, increased amount of IL-6 inflammatory cytokine had negative correlation with the number of NK cells [<xref ref-type="bibr" rid="CR52">52</xref>]. Thus, it is assumed that adoptive transfer of NK cells may have an effective therapeutic approach. Therefore, recently, an ongoing phase I clinical trial has been registered in which NK cell therapy in combination with conventional therapies for COVID-19 patients was proposed (NCT04280224). Altogether, it seems that cell-mediated immunity plays an important role in host immune response against SARS-CoV-2 [<xref ref-type="bibr" rid="CR57">57</xref>].</p></sec><sec id="Sec8"><title>Mesenchymal stromal cells</title><p id="Par16">Persistence of inflammatory cytokines in COVID-19 patients leads to lung dysfunction and even death. Using corticosteroids for dampening cytokine storm suppresses immune system and makes delay in virus elimination [<xref ref-type="bibr" rid="CR58">58</xref>].</p><p id="Par17">Mesenchymal stromal cells (MSCs) are characterized with their immunomodulatory and anti-inflammatory properties [<xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR60">60</xref>]. Because of these characteristics, they have been used for the treatment of various inflammatory and autoimmune disorders including diabetes, graft-versus-host disease (GvHD), and multiple sclerosis [<xref ref-type="bibr" rid="CR59">59</xref>]. It is proven that MSCs and MSC extracellular vesicle (EV) infusion have beneficial effects in the treatment of virus-induced pneumonia by reducing the lung inflammation [<xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR62">62</xref>]. EVs are stable, could distribute to the lungs, and have the same immunomodulatory and anti-inflammatory properties of parental MSCs [<xref ref-type="bibr" rid="CR63">63</xref>]. MSCs decreased inflammatory cytokines and chemokines in animal model of avian influenza. They could also prevent immune cell infiltration into the lungs and improved alveolar injury [<xref ref-type="bibr" rid="CR61">61</xref>]. Recently, there are studies evaluating allogenic MSCs and MSC-derived exosomes as potential therapeutic tools for reducing inflammation and improving COVID-19-related ARDS [<xref ref-type="bibr" rid="CR47">47</xref>, <xref ref-type="bibr" rid="CR64">64</xref>]. It is indicated that adoptive transfer of allogenic umbilical cord mesenchymal stem cells (UC-MSCs) could inhibit inflammation and attenuate symptoms in patients with advanced COVID-19. Four days after cell therapy, patients are disconnected from the ventilator. UC-MSC therapy also elevated T cell numbers and boosted the immune system [<xref ref-type="bibr" rid="CR58">58</xref>]. Administration of ACE negative MSCs to seven COVID-19 patients improved clinical symptoms with no side effects just 2 days after injection. The number of inflammatory cytokine secreting cells reduced significantly. Regulatory DC subpopulation (CD14+CD11c+CD11b<sup>mid</sup>) elevated. The levels of IL-10 anti-inflammatory cytokine increased while TNF-&#x003b1; decreased [<xref ref-type="bibr" rid="CR65">65</xref>]. Infusion of MSCs also induced lung tissue regeneration by modulating inflammatory microenvironment in COVID-19 patients [<xref ref-type="bibr" rid="CR66">66</xref>]. There are several ongoing clinical trials using different sources of MSCs for the treatment of COVID-19 (Table <xref rid="Tab1" ref-type="table">1</xref>). Taken together, MSC therapy could inhibit excessive immune system reaction, modulate inflammatory milieu, and prevent virus-mediated cytokine storm [<xref ref-type="bibr" rid="CR65">65</xref>]. It seems that MSC therapy could be a novel therapeutic approach for the treatment of COVID-19 [<xref ref-type="bibr" rid="CR64">64</xref>].</p></sec><sec id="Sec9"><title>Nanomedicine</title><p id="Par18">LIF (leukemia inhibitory factor) is one of the important cytokines to protect the respiratory system and promote lung homeostasis during viral infections [<xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. This cytokine modulates severe adverse events during ARDS [<xref ref-type="bibr" rid="CR67">67</xref>]. Up to now, there is no study investigating the role of LIF in SARS-CoV-2 infection. However, in respiratory syncytial virus (RSV) model, it has been shown that overexpression of LIF enhanced the recovery of lungs during pneumonia. Neutralization of the LIF induced alveolar damage and chemokine secretion [<xref ref-type="bibr" rid="CR69">69</xref>]. According to these data, LIF might also have protective effects in SARS-CoV-2 infection.</p><p id="Par19">LIF nanoparticles (LIF-NPs) indicated clinical benefits in experimental autoimmune encephalomyelitis (EAE) animal models. LIF-NPs possessed immunomodulatory effects and increased self-tolerance in animal models for ARDS [<xref ref-type="bibr" rid="CR70">70</xref>]. These inhalable NPs could be a novel strategy for lung tissue repair and cytokine storm inhibition [<xref ref-type="bibr" rid="CR64">64</xref>]. Activation and polarization of macrophages play a major role in the initiation and intensity of inflammation, respectively, in ALI/ARDS. Peptide-coated gold nanoparticles could alleviate lung inflammation through inducing M1-to-M2 macrophage phenotype transition and increasing the anti-inflammatory cytokine (IL-10) in the lung of acute lung injury (ALI) mice [<xref ref-type="bibr" rid="CR71">71</xref>].</p></sec><sec id="Sec10"><title>Decoy biomolecules</title><p id="Par20">As mentioned above, SARS-COV-2 attaches to ACE2 receptor to invade the host cells, particularly alveolar epithelial cells. SARS-CoV-2 spike protein has strong affinity to ACE2 receptor [<xref ref-type="bibr" rid="CR72">72</xref>&#x02013;<xref ref-type="bibr" rid="CR74">74</xref>]. This attachment may enhance viral entry and replication [<xref ref-type="bibr" rid="CR74">74</xref>, <xref ref-type="bibr" rid="CR75">75</xref>]. It is assumed that targeting this interaction and using soluble form of ACE2 could be a potential therapeutic approach [<xref ref-type="bibr" rid="CR76">76</xref>]. Studies on COVID-19 indicated that ACE2 injection could competitively neutralize the virus and improve lung injury [<xref ref-type="bibr" rid="CR77">77</xref>]. Recently, a novel therapeutic approach was developed based on soluble ACE2 interaction with the virus. It has been shown that human recombinant soluble ACE2 (hrsACE2) could inhibit SARS-CoV-2 from entering the host cells, decreasing the viral load in a dose-dependent manner. This molecule inhibits viral infection of human blood vessels and kidney organoids. These data indicated that hrsACE2 was effective in early-stage patients [<xref ref-type="bibr" rid="CR78">78</xref>]. Since the inhibitory effects of hrsACE2 were not complete, it is preliminarily considered that the virus may use a second receptor or co-factor such as transmembrane protease serine 2 (TMPRSS2) [<xref ref-type="bibr" rid="CR79">79</xref>]. In this regard, TMPRSS2 inhibitor was approved for clinical application in COVID-19 to inhibit the entry of virus [<xref ref-type="bibr" rid="CR74">74</xref>].</p></sec><sec id="Sec11"><title>Antiviral drugs</title><p id="Par21">Remdesivir is claimed to be an option to treat COVID-19 [<xref ref-type="bibr" rid="CR80">80</xref>]. It is a nucleoside analog and has broad-spectrum activities against RNA viruses such as MERS; remdesivir can effectively diminish the viral load in lung tissue infected with MERS-CoV and improve lung function in animal model [<xref ref-type="bibr" rid="CR81">81</xref>]. The in vitro study revealed that, compared with ribavirin or favipiravir, remdesivir in combination with emetine showed the inhibition in viral yield that might achieve 64.9% [<xref ref-type="bibr" rid="CR82">82</xref>]. Regarding its clinical application, Grein et al. reported the good improvement among severe COVID-19 cases (68%, <italic>n</italic> = 53) after treatment with remdesivir [<xref ref-type="bibr" rid="CR83">83</xref>]. It also showed promising results in the treatment of a patient with COVID-19 in the USA [<xref ref-type="bibr" rid="CR84">84</xref>]. However, its efficacy is doubted because, e.g., in a randomized, double-blind, placebo-controlled, multicenter trial, Wang et al. reported no statistically significant clinical benefits [<xref ref-type="bibr" rid="CR85">85</xref>].</p><p id="Par22">Chloroquine is a drug used to treat malaria [<xref ref-type="bibr" rid="CR86">86</xref>]. It is taught that chloroquine has a great potential to treat COVID-19 [<xref ref-type="bibr" rid="CR87">87</xref>]; chloroquine can prevent pH-dependent steps of the replication of several viruses such as SARS-CoV [<xref ref-type="bibr" rid="CR88">88</xref>]. Additionally, chloroquine has immunomodulatory effects by suppressing the production/release of TNF-&#x003b1; and IL-6. It also might interfere with viral infection and replication, as an autophagy inhibitor [<xref ref-type="bibr" rid="CR89">89</xref>]. In preprinted paper, Chen et al. showed that hydroxychloroquine use can shorten the time to clinical recovery in COVID-19 patients [<xref ref-type="bibr" rid="CR90">90</xref>]. Gautret et al. claimed that the treatment of COVID-19 patients with hydroxychloroquine (chloroquine analog) caused the significant viral load reduction/disappearance [<xref ref-type="bibr" rid="CR91">91</xref>]. However, other researchers did not reveal the same effect. Moreover, high-dose chloroquine diphosphate in combination with azithromycin or oseltamivir resulted in high rates of death and adverse cardiac events [<xref ref-type="bibr" rid="CR92">92</xref>]. Clinicians also cautioned that the increased consumption of chloroquine and hydroxychloroquine can lead to their shortage that might create a problem for people suffering systemic lupus erythematosus, other rheumatological disorders, primary Sj&#x000f6;gren syndrome, dermatological diseases, and antiphospholipid syndrome [<xref ref-type="bibr" rid="CR93">93</xref>].</p><p id="Par23">It has been previously reported that the protease inhibitors such as lopinavir and ritonavir, used to treat infection with human immunodeficiency virus (HIV) [<xref ref-type="bibr" rid="CR94">94</xref>], could improve the outcome of MERS-CoV- [<xref ref-type="bibr" rid="CR95">95</xref>] and SARS-CoV [<xref ref-type="bibr" rid="CR96">96</xref>]&#x02013;infected patients. Initially, lopinavir and ritonavir were hypothesized to inhibit the 3-chymotrypsin-like protease of SARS and MERS, and seemed to be associated with improved outcomes of patients with SARS in a non-randomized open-label trial. In a case report from Korea, it has been shown that the viral loads of a SARS-CoV-2 significantly decreased after lopinavir/ritonavir treatment [<xref ref-type="bibr" rid="CR97">97</xref>]. However, it is controversial whether HIV protease inhibitors could effectively inhibit the 3-chymotrypsin-like and papain-like proteases of SARS-CoV-2. HIV protease belongs to the aspartic protease family, whereas the two coronavirus proteases are from the cysteine protease family. Moreover, HIV protease inhibitors were specifically optimized to fit the C2 symmetry in the catalytic site of the HIV protease dimer; however, this C2-symmetric pocket is absent in coronavirus proteases. If HIV protease inhibitors alter host pathways to indirectly interfere with coronavirus infections, their potency remains a concern [<xref ref-type="bibr" rid="CR98">98</xref>].</p><p id="Par24">Favipiravir is a new type of RNA-dependent RNA polymerase inhibitor. Additionally, it is capable of blocking the replication of other RNA viruses [<xref ref-type="bibr" rid="CR99">99</xref>]. Favipiravir is converted into an active phosphoribosylated form (favipiravir-RTP) in cells and is recognized as a substrate by viral RNA polymerase, therefore inhibiting RNA polymerase activity [<xref ref-type="bibr" rid="CR100">100</xref>]. Favipiravir may have potential antiviral action on SARS-CoV-2, which is a RNA virus. In a clinical trial on favipiravir for the treatment of COVID-19, the preliminary results indicated that favipiravir had more potent antiviral action than lopinavir/ritonavir [<xref ref-type="bibr" rid="CR101">101</xref>].</p></sec><sec id="Sec12"><title>BCG vaccine</title><p id="Par25">Bacillus Calmette-Gu&#x000e9;rin (BCG; weakened strain of <italic>Mycobacterium bovis</italic>) vaccination could have protective effects against COVID-19 infection. There are several mechanisms that ensure BCG-induced non-specific protection and are actively studied. BCG and viral antigens have similar molecular structure; so after vaccination, B and T cells can recognize both pathogen types. Moreover, BCG vaccination results in the so-called trained immunity&#x02014;epigenetic reprogramming of innate immune cell types [<xref ref-type="bibr" rid="CR102">102</xref>]. Monocytes of vaccinated individuals had higher expression of different surface markers of activation and synthesis of cytokines (IL-1&#x003b2;, IL-6, IFN&#x003b3;, and TNF) in response to infection than those of non-vaccinated ones; so non-mycobacterium pathogens, e.g., staphylococci, yellow fever virus, and influenza, can be removed faster [<xref ref-type="bibr" rid="CR103">103</xref>]. In several preprints, it is claimed that BCG vaccination program could reduce the number of SARS-CoV-2-infected individuals and their mortality [<xref ref-type="bibr" rid="CR104">104</xref>, <xref ref-type="bibr" rid="CR105">105</xref>]. However, the WHO does not recommend BCG vaccination to prevent COVID-19 because there is still no direct evidence that it can protect against SARS-CoV-2 infection, and all related clinical trials are ongoing [<xref ref-type="bibr" rid="CR106">106</xref>].</p></sec><sec id="Sec13"><title>Corticosteroids</title><p id="Par26">Corticosteroids are well-known with their immunosuppressive activity, which are essential to stop or delay the progression of the pneumonia and have been proved to be beneficial for the treatment of ARDS [<xref ref-type="bibr" rid="CR107">107</xref>]. Additionally, corticosteroids have an anti-inflammatory effect to diminish systemic inflammation, reduce exudative fluid in the lung tissue, and inhibit further diffused alveolar damage, which can relieve hypoxemia which can protect the lungs effectively and prevent further progression of respiratory insufficiency [<xref ref-type="bibr" rid="CR108">108</xref>]. The use of corticosteroids for the treatment of COVID-19 is controversial due to their negative impact on anti-viral immune responses [<xref ref-type="bibr" rid="CR109">109</xref>]. However, it has been shown that corticosteroids could improve mortality in severe COVID-19 patients with systemic hyperinflammation [<xref ref-type="bibr" rid="CR110">110</xref>]. It is supposed that patient selection, half-life, formulation, and dosage of the corticosteroids are important factors determining the clinical outcome. In this regard, a preprinted study indicated that in severe COVID-19 patients with ARDS early short-term and low dose of corticosteroid (methylprednisolone) improved clinical manifestation and long lesions [<xref ref-type="bibr" rid="CR111">111</xref>].</p></sec></sec><sec id="Sec14"><title>Conclusion</title><p id="Par27">Although it seems that antiviral drugs are effective in improving clinical manifestation and controlling the SARS-CoV-2 infection, until now, there is no definite treatment protocol for this novel virus infection. Lymphocytopenia alongside with excessive inflammation and cytokine storm followed by ARDS in these patients are still unsolved problems that cause severity of the disease [<xref ref-type="bibr" rid="CR14">14</xref>]. Therefore, it is considered that immune response modulation and inflammation management are essential steps. Based on the abovementioned, more studies needed to be conducted on immunopathogenesis and immune response during the SARS-CoV-2 infection. In this regard, new therapeutic approaches including mesenchymal stromal cell therapy and immune cell therapy showed promising results.</p></sec></body><back><fn-group><fn><p><bold>Publisher&#x02019;s note</bold></p><p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p></fn></fn-group><notes notes-type="ethics"><title>Compliance with ethical standards</title><notes id="FPar1" notes-type="COI-statement"><title>Conflict of interest</title><p id="Par28">The authors declare that they have no conflict of interest.</p></notes></notes><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><mixed-citation publication-type="other">Zhang L, Liu Y (2020) Potential interventions for novel coronavirus in China: a systematic review. J Med Virol</mixed-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S</given-names></name><etal/></person-group><article-title>Coronaviruses and the associated potential therapeutics for the viral infections</article-title><source>J Infect Dis Ther</source><year>2020</year><volume>8</volume><issue>417</issue><fpage>2</fpage></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shanmugaraj</surname><given-names>B</given-names></name><name><surname>Malla</surname><given-names>A</given-names></name><name><surname>Phoolcharoen</surname><given-names>W</given-names></name></person-group><article-title>Emergence of novel coronavirus 2019-nCoV: need for rapid vaccine and biologics development</article-title><source>Pathogens</source><year>2020</year><volume>9</volume><issue>2</issue><fpage>148</fpage></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Fan</surname><given-names>Y</given-names></name><name><surname>Lai</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>T</given-names></name><name><surname>Li</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>P</given-names></name><name><surname>Pan</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>Q</given-names></name><name><surname>Wu</surname><given-names>J</given-names></name></person-group><article-title>Coronavirus infections and immune responses</article-title><source>J Med Virol</source><year>2020</year><volume>92</volume><issue>4</issue><fpage>424</fpage><lpage>432</lpage><?supplied-pmid 31981224?><pub-id pub-id-type="pmid">31981224</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><mixed-citation publication-type="other">Cai Q, Yang M, Liu D, Chen J, Shu D, Xia J, Liao X, Gu Y, Cai Q, Yang Y, Shen C, Li X, Peng L, Huang D, Zhang J, Zhang S, Wang F, Liu J, Chen L, Chen S, Wang Z, Zhang Z, Cao R, Zhong W, Liu Y, Liu L (2020) Experimental treatment with favipiravir for COVID-19: an open-label control study. Engineering</mixed-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiel</surname><given-names>V</given-names></name><name><surname>Weber</surname><given-names>F</given-names></name></person-group><article-title>Interferon and cytokine responses to SARS-coronavirus infection</article-title><source>Cytokine Growth Factor Rev</source><year>2008</year><volume>19</volume><issue>2</issue><fpage>121</fpage><lpage>132</lpage><?supplied-pmid 18321765?><pub-id pub-id-type="pmid">18321765</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><mixed-citation publication-type="other">Wang D et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus&#x02013;infected pneumonia in Wuhan, China. Jama</mixed-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heymann</surname><given-names>DL</given-names></name><name><surname>Shindo</surname><given-names>N</given-names></name></person-group><article-title>COVID-19: what is next for public health?</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10224</issue><fpage>542</fpage><lpage>545</lpage><?supplied-pmid 32061313?><pub-id pub-id-type="pmid">32061313</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><mixed-citation publication-type="other">Yu F et al (2020) Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China. Microbes Infect</mixed-citation></ref><ref id="CR10"><label>10.</label><mixed-citation publication-type="other">Yan R et al (2020) Structural basis for the recognition of the SARS-CoV-2 by full-length human ACE2. Science</mixed-citation></ref><ref id="CR11"><label>11.</label><mixed-citation publication-type="other">Zhu R-F et al Systematic review of the registered clinical trials of coronavirus diseases 2019 (COVID-19). medRxiv:2020</mixed-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frieman</surname><given-names>M</given-names></name><name><surname>Heise</surname><given-names>M</given-names></name><name><surname>Baric</surname><given-names>R</given-names></name></person-group><article-title>SARS coronavirus and innate immunity</article-title><source>Virus Res</source><year>2008</year><volume>133</volume><issue>1</issue><fpage>101</fpage><lpage>112</lpage><?supplied-pmid 17451827?><pub-id pub-id-type="pmid">17451827</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Wei</surname><given-names>Q</given-names></name><name><surname>Nishiura</surname><given-names>K</given-names></name><name><surname>Peng</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Midkiff</surname><given-names>C</given-names></name><name><surname>Alvarez</surname><given-names>X</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Lackner</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name></person-group><article-title>Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques</article-title><source>Mucosal Immunol</source><year>2016</year><volume>9</volume><issue>4</issue><fpage>1089</fpage><lpage>1101</lpage><?supplied-pmid 26647718?><pub-id pub-id-type="pmid">26647718</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Qin</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yan</surname><given-names>X</given-names></name><name><surname>Zeng</surname><given-names>X</given-names></name><name><surname>Zhang</surname><given-names>S</given-names></name></person-group><article-title>The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China</article-title><source>Clin Immunol</source><year>2020</year><volume>214</volume><fpage>108393</fpage><?supplied-pmid 32222466?><pub-id pub-id-type="pmid">32222466</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Janice Oh</surname><given-names>H-L</given-names></name><name><surname>Ken-En Gan</surname><given-names>S</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>YJ</given-names></name></person-group><article-title>Understanding the T cell immune response in SARS coronavirus infection</article-title><source>Emerg Microbes Infect</source><year>2012</year><volume>1</volume><issue>1</issue><fpage>1</fpage><lpage>6</lpage></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>O-W</given-names></name><name><surname>Chia</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>AT</given-names></name><name><surname>Jadi</surname><given-names>RS</given-names></name><name><surname>Leong</surname><given-names>HN</given-names></name><name><surname>Bertoletti</surname><given-names>A</given-names></name><name><surname>Tan</surname><given-names>YJ</given-names></name></person-group><article-title>Memory T cell responses targeting the SARS coronavirus persist up to 11 years post-infection</article-title><source>Vaccine</source><year>2016</year><volume>34</volume><issue>17</issue><fpage>2008</fpage><lpage>2014</lpage><?supplied-pmid 26954467?><pub-id pub-id-type="pmid">26954467</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>WJ</given-names></name><name><surname>Lan</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>H</given-names></name><name><surname>Bao</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Chai</surname><given-names>Y</given-names></name><name><surname>Qi</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Meng</surname><given-names>S</given-names></name><name><surname>Qin</surname><given-names>C</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name></person-group><article-title>Protective T cell responses featured by concordant recognition of Middle East respiratory syndrome coronavirus&#x02013;derived CD8+ T cell epitopes and host MHC</article-title><source>J Immunol</source><year>2017</year><volume>198</volume><issue>2</issue><fpage>873</fpage><lpage>882</lpage><?supplied-pmid 27903740?><pub-id pub-id-type="pmid">27903740</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>WJ</given-names></name><name><surname>Zhao</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>K</given-names></name><name><surname>Xu</surname><given-names>K</given-names></name><name><surname>Wong</surname><given-names>G</given-names></name><name><surname>Tan</surname><given-names>W</given-names></name><name><surname>Gao</surname><given-names>GF</given-names></name></person-group><article-title>T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV</article-title><source>Antivir Res</source><year>2017</year><volume>137</volume><fpage>82</fpage><lpage>92</lpage><?supplied-pmid 27840203?><pub-id pub-id-type="pmid">27840203</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><mixed-citation publication-type="other">Diao B et al (2020) Reduction and functional exhaustion of T cells in patients with coronavirus disease 2019 (COVID-19). medRxiv</mixed-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McLane</surname><given-names>LM</given-names></name><name><surname>Abdel-Hakeem</surname><given-names>MS</given-names></name><name><surname>Wherry</surname><given-names>EJ</given-names></name></person-group><article-title>CD8 T cell exhaustion during chronic viral infection and cancer</article-title><source>Annu Rev Immunol</source><year>2019</year><volume>37</volume><fpage>457</fpage><lpage>495</lpage><?supplied-pmid 30676822?><pub-id pub-id-type="pmid">30676822</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Ren</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Xia</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><name><surname>Xie</surname><given-names>X</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Xiao</surname><given-names>Y</given-names></name><name><surname>Gao</surname><given-names>H</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Xie</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>G</given-names></name><name><surname>Jiang</surname><given-names>R</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Jin</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name></person-group><article-title>Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10223</issue><fpage>497</fpage><lpage>506</lpage><?supplied-pmid 7159299?><pub-id pub-id-type="pmid">31986264</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><mixed-citation publication-type="other">Zheng M et al (2020) Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol:1&#x02013;3</mixed-citation></ref><ref id="CR23"><label>23.</label><mixed-citation publication-type="other">Zhou Y et al (2020) Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+ CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. bioRxiv</mixed-citation></ref><ref id="CR24"><label>24.</label><mixed-citation publication-type="other">Vetter P, Eckerle I, Kaiser L (2020) Covid-19: a puzzle with many missing pieces. British Medical Journal Publishing Group</mixed-citation></ref><ref id="CR25"><label>25.</label><mixed-citation publication-type="other">Casadevall A, Pirofski L-a (2020) The convalescent sera option for containing COVID-19. J Clin Invest 130(4)</mixed-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>X-X</given-names></name><name><surname>Gao</surname><given-names>HN</given-names></name><name><surname>Wu</surname><given-names>HB</given-names></name><name><surname>Peng</surname><given-names>XM</given-names></name><name><surname>Ou</surname><given-names>HL</given-names></name><name><surname>Li</surname><given-names>LJ</given-names></name></person-group><article-title>Successful treatment of avian-origin influenza A (H7N9) infection using convalescent plasma</article-title><source>Int J Infect Dis</source><year>2015</year><volume>41</volume><fpage>3</fpage><lpage>5</lpage><?supplied-pmid 26482389?><pub-id pub-id-type="pmid">26482389</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Beigel</surname><given-names>JH</given-names></name><name><surname>Voell</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Raviprakash</surname><given-names>K</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Jiao</surname><given-names>JA</given-names></name><name><surname>Sullivan</surname><given-names>E</given-names></name><name><surname>Luke</surname><given-names>T</given-names></name><name><surname>Davey</surname><given-names>RT</given-names><suffix>Jr</suffix></name></person-group><article-title>Safety and tolerability of a novel, polyclonal human anti-MERS coronavirus antibody produced from transchromosomic cattle: a phase 1 randomised, double-blind, single-dose-escalation study</article-title><source>Lancet Infect Dis</source><year>2018</year><volume>18</volume><issue>4</issue><fpage>410</fpage><lpage>418</lpage><?supplied-pmid 29329957?><pub-id pub-id-type="pmid">29329957</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol</article-title><source>Springerplus</source><year>2015</year><volume>4</volume><issue>1</issue><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">25674489</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Doremalen</surname><given-names>N</given-names></name><name><surname>Falzarano</surname><given-names>D</given-names></name><name><surname>Ying</surname><given-names>T</given-names></name><name><surname>de Wit</surname><given-names>E</given-names></name><name><surname>Bushmaker</surname><given-names>T</given-names></name><name><surname>Feldmann</surname><given-names>F</given-names></name><name><surname>Okumura</surname><given-names>A</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Scott</surname><given-names>DP</given-names></name><name><surname>Hanley</surname><given-names>PW</given-names></name><name><surname>Feldmann</surname><given-names>H</given-names></name><name><surname>Dimitrov</surname><given-names>DS</given-names></name><name><surname>Munster</surname><given-names>VJ</given-names></name></person-group><article-title>Efficacy of antibody-based therapies against Middle East respiratory syndrome coronavirus (MERS-CoV) in common marmosets</article-title><source>Antivir Res</source><year>2017</year><volume>143</volume><fpage>30</fpage><lpage>37</lpage><?supplied-pmid 28389142?><pub-id pub-id-type="pmid">28389142</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>G</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name></person-group><article-title>Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2</article-title><source>Int J Biol Sci</source><year>2020</year><volume>16</volume><issue>10</issue><fpage>1718</fpage><lpage>1723</lpage><?supplied-pmid 32226289?><pub-id pub-id-type="pmid">32226289</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>C</given-names></name><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Yu</surname><given-names>T</given-names></name><name><surname>Qu</surname><given-names>J</given-names></name><name><surname>Zhou</surname><given-names>M</given-names></name><name><surname>Chen</surname><given-names>L</given-names></name><name><surname>Meng</surname><given-names>S</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Peng</surname><given-names>C</given-names></name><name><surname>Yuan</surname><given-names>M</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>Z</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>Gao</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>B</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>W</given-names></name><name><surname>Peng</surname><given-names>Y</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Lin</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Huang</surname><given-names>S</given-names></name><name><surname>Zhou</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Deng</surname><given-names>K</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Gong</surname><given-names>Q</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Zheng</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Zhou</surname><given-names>D</given-names></name><name><surname>Yu</surname><given-names>D</given-names></name><name><surname>Hou</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>Z</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name></person-group><article-title>Effectiveness of convalescent plasma therapy in severe COVID-19 patients</article-title><source>Proc Natl Acad Sci</source><year>2020</year><volume>117</volume><issue>17</issue><fpage>9490</fpage><lpage>9496</lpage><?supplied-pmid 32253318?><pub-id pub-id-type="pmid">32253318</pub-id></element-citation></ref><ref id="CR32"><label>32.</label><mixed-citation publication-type="other">Tiberghien P, Lamballerie X, Morel P, Gallian P, Lacombe K, Yazdanpanah Y (2020) Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how. Vox Sang</mixed-citation></ref><ref id="CR33"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>S-F</given-names></name><name><surname>Tseng</surname><given-names>SP</given-names></name><name><surname>Yen</surname><given-names>CH</given-names></name><name><surname>Yang</surname><given-names>JY</given-names></name><name><surname>Tsao</surname><given-names>CH</given-names></name><name><surname>Shen</surname><given-names>CW</given-names></name><name><surname>Chen</surname><given-names>KH</given-names></name><name><surname>Liu</surname><given-names>FT</given-names></name><name><surname>Liu</surname><given-names>WT</given-names></name><name><surname>Chen</surname><given-names>YMA</given-names></name><name><surname>Huang</surname><given-names>JC</given-names></name></person-group><article-title>Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins</article-title><source>Biochem Biophys Res Commun</source><year>2014</year><volume>451</volume><issue>2</issue><fpage>208</fpage><lpage>214</lpage><?supplied-pmid 25073113?><pub-id pub-id-type="pmid">25073113</pub-id></element-citation></ref><ref id="CR34"><label>34.</label><mixed-citation publication-type="other">Zand M and J Wang Potential mechanisms of age related severity of COVID-19 infection: implications for vaccine development and convalescent serum therapy<italic>.</italic> 2020.</mixed-citation></ref><ref id="CR35"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bakker</surname><given-names>AB</given-names></name><etal/></person-group><article-title>Novel human monoclonal antibody combination effectively neutralizing natural rabies virus variants and individual in vitro escape mutants</article-title><source>J Virol</source><year>2005</year><volume>79</volume><issue>14</issue><fpage>9062</fpage><lpage>9068</lpage><?supplied-pmid 15994800?><pub-id pub-id-type="pmid">15994800</pub-id></element-citation></ref><ref id="CR36"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sneller</surname><given-names>MC</given-names></name><etal/></person-group><article-title>An open-label phase 1 clinical trial of the anti-&#x003b1;4&#x003b2;7 monoclonal antibody vedolizumab in HIV-infected individuals</article-title><source>Sci Transl Med</source><year>2019</year><volume>11</volume><issue>509</issue><fpage>eaax3447</fpage><?supplied-pmid 31488581?><pub-id pub-id-type="pmid">31488581</pub-id></element-citation></ref><ref id="CR37"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Lei</surname><given-names>C</given-names></name><name><surname>Hu</surname><given-names>D</given-names></name><name><surname>Dimitrov</surname><given-names>DS</given-names></name><name><surname>Ying</surname><given-names>T</given-names></name></person-group><article-title>Human monoclonal antibodies as candidate therapeutics against emerging viruses</article-title><source>Front Med</source><year>2017</year><volume>11</volume><issue>4</issue><fpage>462</fpage><lpage>470</lpage><?supplied-pmid 29159596?><pub-id pub-id-type="pmid">29159596</pub-id></element-citation></ref><ref id="CR38"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Passini</surname><given-names>N</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Zambon</surname><given-names>M</given-names></name></person-group><article-title>Rapid generation of a human monoclonal antibody to combat Middle East respiratory syndrome</article-title><source>J Infect Public Health</source><year>2016</year><volume>9</volume><issue>3</issue><fpage>231</fpage><lpage>235</lpage><?supplied-pmid 27102927?><pub-id pub-id-type="pmid">27102927</pub-id></element-citation></ref><ref id="CR39"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhu</surname><given-names>Z</given-names></name><name><surname>Chakraborti</surname><given-names>S</given-names></name><name><surname>He</surname><given-names>Y</given-names></name><name><surname>Roberts</surname><given-names>A</given-names></name><name><surname>Sheahan</surname><given-names>T</given-names></name><name><surname>Xiao</surname><given-names>X</given-names></name><name><surname>Hensley</surname><given-names>LE</given-names></name><name><surname>Prabakaran</surname><given-names>P</given-names></name><name><surname>Rockx</surname><given-names>B</given-names></name><name><surname>Sidorov</surname><given-names>IA</given-names></name><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Vogel</surname><given-names>L</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Kim</surname><given-names>JO</given-names></name><name><surname>Wang</surname><given-names>LF</given-names></name><name><surname>Baric</surname><given-names>R</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name><name><surname>Curtis</surname><given-names>KM</given-names></name><name><surname>Nabel</surname><given-names>GJ</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name><name><surname>Jiang</surname><given-names>S</given-names></name><name><surname>Dimitrov</surname><given-names>DS</given-names></name></person-group><article-title>Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies</article-title><source>Proc Natl Acad Sci</source><year>2007</year><volume>104</volume><issue>29</issue><fpage>12123</fpage><lpage>12128</lpage><?supplied-pmid 17620608?><pub-id pub-id-type="pmid">17620608</pub-id></element-citation></ref><ref id="CR40"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sui</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>W</given-names></name><name><surname>Murakami</surname><given-names>A</given-names></name><name><surname>Tamin</surname><given-names>A</given-names></name><name><surname>Matthews</surname><given-names>LJ</given-names></name><name><surname>Wong</surname><given-names>SK</given-names></name><name><surname>Moore</surname><given-names>MJ</given-names></name><name><surname>Tallarico</surname><given-names>ASC</given-names></name><name><surname>Olurinde</surname><given-names>M</given-names></name><name><surname>Choe</surname><given-names>H</given-names></name><name><surname>Anderson</surname><given-names>LJ</given-names></name><name><surname>Bellini</surname><given-names>WJ</given-names></name><name><surname>Farzan</surname><given-names>M</given-names></name><name><surname>Marasco</surname><given-names>WA</given-names></name></person-group><article-title>Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association</article-title><source>Proc Natl Acad Sci</source><year>2004</year><volume>101</volume><issue>8</issue><fpage>2536</fpage><lpage>2541</lpage><?supplied-pmid 14983044?><pub-id pub-id-type="pmid">14983044</pub-id></element-citation></ref><ref id="CR41"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traggiai</surname><given-names>E</given-names></name><name><surname>Becker</surname><given-names>S</given-names></name><name><surname>Subbarao</surname><given-names>K</given-names></name><name><surname>Kolesnikova</surname><given-names>L</given-names></name><name><surname>Uematsu</surname><given-names>Y</given-names></name><name><surname>Gismondo</surname><given-names>MR</given-names></name><name><surname>Murphy</surname><given-names>BR</given-names></name><name><surname>Rappuoli</surname><given-names>R</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><article-title>An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus</article-title><source>Nat Med</source><year>2004</year><volume>10</volume><issue>8</issue><fpage>871</fpage><lpage>875</lpage><?supplied-pmid 15247913?><pub-id pub-id-type="pmid">15247913</pub-id></element-citation></ref><ref id="CR42"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Corti</surname><given-names>D</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Pedotti</surname><given-names>M</given-names></name><name><surname>Simonelli</surname><given-names>L</given-names></name><name><surname>Agnihothram</surname><given-names>S</given-names></name><name><surname>Fett</surname><given-names>C</given-names></name><name><surname>Fernandez-Rodriguez</surname><given-names>B</given-names></name><name><surname>Foglierini</surname><given-names>M</given-names></name><name><surname>Agatic</surname><given-names>G</given-names></name><name><surname>Vanzetta</surname><given-names>F</given-names></name><name><surname>Gopal</surname><given-names>R</given-names></name><name><surname>Langrish</surname><given-names>CJ</given-names></name><name><surname>Barrett</surname><given-names>NA</given-names></name><name><surname>Sallusto</surname><given-names>F</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><name><surname>Varani</surname><given-names>L</given-names></name><name><surname>Zambon</surname><given-names>M</given-names></name><name><surname>Perlman</surname><given-names>S</given-names></name><name><surname>Lanzavecchia</surname><given-names>A</given-names></name></person-group><article-title>Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus</article-title><source>Proc Natl Acad Sci</source><year>2015</year><volume>112</volume><issue>33</issue><fpage>10473</fpage><lpage>10478</lpage><?supplied-pmid 26216974?><pub-id pub-id-type="pmid">26216974</pub-id></element-citation></ref><ref id="CR43"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luke</surname><given-names>T</given-names></name><etal/></person-group><article-title>Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo</article-title><source>Sci Transl Med</source><year>2016</year><volume>8</volume><issue>326</issue><fpage>326ra21-326ra21</fpage></element-citation></ref><ref id="CR44"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Johnson</surname><given-names>RF</given-names></name><name><surname>Bagci</surname><given-names>U</given-names></name><name><surname>Keith</surname><given-names>L</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Mollura</surname><given-names>DJ</given-names></name><name><surname>Zeitlin</surname><given-names>L</given-names></name><name><surname>Qin</surname><given-names>J</given-names></name><name><surname>Huzella</surname><given-names>L</given-names></name><name><surname>Bartos</surname><given-names>CJ</given-names></name><name><surname>Bohorova</surname><given-names>N</given-names></name><name><surname>Bohorov</surname><given-names>O</given-names></name><name><surname>Goodman</surname><given-names>C</given-names></name><name><surname>Kim</surname><given-names>DH</given-names></name><name><surname>Paulty</surname><given-names>MH</given-names></name><name><surname>Velasco</surname><given-names>J</given-names></name><name><surname>Whaley</surname><given-names>KJ</given-names></name><name><surname>Johnson</surname><given-names>JC</given-names></name><name><surname>Pettitt</surname><given-names>J</given-names></name><name><surname>Ork</surname><given-names>BL</given-names></name><name><surname>Solomon</surname><given-names>J</given-names></name><name><surname>Oberlander</surname><given-names>N</given-names></name><name><surname>Zhu</surname><given-names>Q</given-names></name><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Holbrook</surname><given-names>MR</given-names></name><name><surname>Olinger</surname><given-names>GG</given-names></name><name><surname>Baric</surname><given-names>RS</given-names></name><name><surname>Hensley</surname><given-names>LE</given-names></name><name><surname>Jahrling</surname><given-names>PB</given-names></name><name><surname>Marasco</surname><given-names>WA</given-names></name></person-group><article-title>3B11-N, a monoclonal antibody against MERS-CoV, reduces lung pathology in rhesus monkeys following intratracheal inoculation of MERS-CoV Jordan-n3/2012</article-title><source>Virology</source><year>2016</year><volume>490</volume><fpage>49</fpage><lpage>58</lpage><?supplied-pmid 26828465?><pub-id pub-id-type="pmid">26828465</pub-id></element-citation></ref><ref id="CR45"><label>45.</label><mixed-citation publication-type="other">Chen W-H, PJ Hotez, and ME Bottazzi Potential for developing the SARS-CoV receptor binding domain recombinant protein (RBD) as a heterologous human vaccine for SARS-CoV-2. 2020</mixed-citation></ref><ref id="CR46"><label>46.</label><mixed-citation publication-type="other">Zheng Z et al (2020) Monoclonal antibodies for the S2 subunit of spike of SARS-CoV cross-react with the newly-emerged SARS-CoV-2. bioRxiv</mixed-citation></ref><ref id="CR47"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zumla</surname><given-names>A</given-names></name><name><surname>Hui</surname><given-names>DS</given-names></name><name><surname>Azhar</surname><given-names>EI</given-names></name><name><surname>Memish</surname><given-names>ZA</given-names></name><name><surname>Maeurer</surname><given-names>M</given-names></name></person-group><article-title>Reducing mortality from 2019-nCoV: host-directed therapies should be an option</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10224</issue><fpage>e35</fpage><lpage>e36</lpage><?supplied-pmid 32035018?><pub-id pub-id-type="pmid">32035018</pub-id></element-citation></ref><ref id="CR48"><label>48.</label><mixed-citation publication-type="other">Xu X et al (2020) Effective treatment of severe COVID-19 patients with tocilizumab, in China. Xiv:20200300026</mixed-citation></ref><ref id="CR49"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiappelli</surname><given-names>F</given-names></name><name><surname>Khakshooy</surname><given-names>A</given-names></name><name><surname>Greenberg</surname><given-names>G</given-names></name></person-group><article-title>CoViD-19 Immunopathology &#x00026; Immunotherapy</article-title><source>Bioinformation</source><year>2020</year><volume>16</volume><issue>3</issue><fpage>219</fpage><lpage>222</lpage><?supplied-pmid 32308263?><pub-id pub-id-type="pmid">32308263</pub-id></element-citation></ref><ref id="CR50"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Richardson</surname><given-names>P</given-names></name><name><surname>Griffin</surname><given-names>I</given-names></name><name><surname>Tucker</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Oechsle</surname><given-names>O</given-names></name><name><surname>Phelan</surname><given-names>A</given-names></name><name><surname>Stebbing</surname><given-names>J</given-names></name></person-group><article-title>Baricitinib as potential treatment for 2019-nCoV acute respiratory disease</article-title><source>Lancet</source><year>2020</year><volume>395</volume><issue>10223</issue><fpage>e30</fpage><lpage>e31</lpage><?supplied-pmid 32032529?><pub-id pub-id-type="pmid">32032529</pub-id></element-citation></ref><ref id="CR51"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stebbing</surname><given-names>J</given-names></name><name><surname>Phelan</surname><given-names>A</given-names></name><name><surname>Griffin</surname><given-names>I</given-names></name><name><surname>Tucker</surname><given-names>C</given-names></name><name><surname>Oechsle</surname><given-names>O</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Richardson</surname><given-names>P</given-names></name></person-group><article-title>COVID-19: combining antiviral and anti-inflammatory treatments</article-title><source>Lancet Infect Dis</source><year>2020</year><volume>20</volume><fpage>400</fpage><lpage>402</lpage><?supplied-pmid 32113509?><pub-id pub-id-type="pmid">32113509</pub-id></element-citation></ref><ref id="CR52"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Nie</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><name><surname>Zhao</surname><given-names>Q</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Song</surname><given-names>S</given-names></name><name><surname>Ma</surname><given-names>Z</given-names></name><name><surname>Mo</surname><given-names>P</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia</article-title><source>J Infect Dis</source><year>2020</year><volume>221</volume><fpage>1762</fpage><lpage>1769</lpage><?supplied-pmid 32227123?><pub-id pub-id-type="pmid">32227123</pub-id></element-citation></ref><ref id="CR53"><label>53.</label><mixed-citation publication-type="other">Liu Z, Long W, Tu M, Chen S, Huang Y, Wang S, Zhou W, Chen D, Zhou L, Wang M, Wu M, Huang Q, Xu H, Zeng W, Guo L (2020) Lymphocyte subset (CD4+, CD8+) counts reflect the severity of infection and predict the clinical outcomes in patients with COVID-19. J Infect</mixed-citation></ref><ref id="CR54"><label>54.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Madera</surname><given-names>S</given-names></name><name><surname>Rapp</surname><given-names>M</given-names></name><name><surname>Firth</surname><given-names>MA</given-names></name><name><surname>Beilke</surname><given-names>JN</given-names></name><name><surname>Lanier</surname><given-names>LL</given-names></name><name><surname>Sun</surname><given-names>JC</given-names></name></person-group><article-title>Type I IFN promotes NK cell expansion during viral infection by protecting NK cells against fratricide</article-title><source>J Exp Med</source><year>2016</year><volume>213</volume><issue>2</issue><fpage>225</fpage><lpage>233</lpage><?supplied-pmid 26755706?><pub-id pub-id-type="pmid">26755706</pub-id></element-citation></ref><ref id="CR55"><label>55.</label><mixed-citation publication-type="other">Shi Y et al (2020) Immunopathological characteristics of coronavirus disease 2019 cases in Guangzhou, China. medRxiv</mixed-citation></ref><ref id="CR56"><label>56.</label><mixed-citation publication-type="other">Wan S et al (2020) Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP). Medrxiv</mixed-citation></ref><ref id="CR57"><label>57.</label><mixed-citation publication-type="other">Weiskopf D et al (2020) Phenotype of SARS-CoV-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome. medRxiv</mixed-citation></ref><ref id="CR58"><label>58.</label><mixed-citation publication-type="other">Liang B et al Clinical remission of a critically ill COVID-19 patient treated by human umbilical cord mesenchymal stem cells</mixed-citation></ref><ref id="CR59"><label>59.</label><mixed-citation publication-type="other">Hashemi SM et al (2019) Investigating the route of administration and efficacy of adipose tissue-derived mesenchymal stem cells and conditioned medium in type 1 diabetic mice. Inflammopharmacology:1&#x02013;17</mixed-citation></ref><ref id="CR60"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hossein-Khannazer</surname><given-names>N</given-names></name><etal/></person-group><article-title>Study of the immunomodulatory effects of osteogenic differentiated human dental pulp stem cells</article-title><source>Life Sci</source><year>2019</year><volume>216</volume><fpage>111</fpage><lpage>118</lpage><?supplied-pmid 30465790?><pub-id pub-id-type="pmid">30465790</pub-id></element-citation></ref><ref id="CR61"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>Y</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Shi</surname><given-names>W</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name><name><surname>Zhu</surname><given-names>L</given-names></name><name><surname>Lu</surname><given-names>W</given-names></name><name><surname>Han</surname><given-names>XD</given-names></name></person-group><article-title>Mesenchymal stromal cell treatment prevents H9N2 avian influenza virus-induced acute lung injury in mice</article-title><source>Stem Cell Res Ther</source><year>2016</year><volume>7</volume><issue>1</issue><fpage>159</fpage><?supplied-pmid 27793190?><pub-id pub-id-type="pmid">27793190</pub-id></element-citation></ref><ref id="CR62"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khatri</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>LA</given-names></name><name><surname>Meulia</surname><given-names>T</given-names></name></person-group><article-title>Mesenchymal stem cell-derived extracellular vesicles attenuate influenza virus-induced acute lung injury in a pig model</article-title><source>Stem Cell Res Ther</source><year>2018</year><volume>9</volume><issue>1</issue><fpage>1</fpage><lpage>13</lpage><pub-id pub-id-type="pmid">29291747</pub-id></element-citation></ref><ref id="CR63"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bari</surname><given-names>E</given-names></name><name><surname>Ferrarotti</surname><given-names>I</given-names></name><name><surname>Saracino</surname><given-names>L</given-names></name><name><surname>Perteghella</surname><given-names>S</given-names></name><name><surname>Torre</surname><given-names>ML</given-names></name><name><surname>Corsico</surname><given-names>AG</given-names></name></person-group><article-title>Mesenchymal stromal cell secretome for severe COVID-19 infections: premises for the therapeutic use</article-title><source>Cells</source><year>2020</year><volume>9</volume><issue>4</issue><fpage>924</fpage></element-citation></ref><ref id="CR64"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metcalfe</surname><given-names>SM</given-names></name></person-group><article-title>Mesenchymal stem cells and management of COVID-19 pneumonia</article-title><source>Med Drug Discov</source><year>2020</year><volume>5</volume><fpage>100019</fpage><?supplied-pmid 32296777?><pub-id pub-id-type="pmid">32296777</pub-id></element-citation></ref><ref id="CR65"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leng</surname><given-names>Z</given-names></name><name><surname>Zhu</surname><given-names>R</given-names></name><name><surname>Hou</surname><given-names>W</given-names></name><name><surname>Feng</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Han</surname><given-names>Q</given-names></name><name><surname>Shan</surname><given-names>G</given-names></name><name><surname>Meng</surname><given-names>F</given-names></name><name><surname>du</surname><given-names>D</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Fan</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Deng</surname><given-names>L</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Zhao</surname><given-names>Y</given-names></name><name><surname>Yin</surname><given-names>K</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Gao</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>B</given-names></name><name><surname>Jin</surname><given-names>R</given-names></name><name><surname>Stambler</surname><given-names>I</given-names></name><name><surname>Lim</surname><given-names>LW</given-names></name><name><surname>Su</surname><given-names>H</given-names></name><name><surname>Moskalev</surname><given-names>A</given-names></name><name><surname>Cano</surname><given-names>A</given-names></name><name><surname>Chakrabarti</surname><given-names>S</given-names></name><name><surname>Min</surname><given-names>KJ</given-names></name><name><surname>Ellison-Hughes</surname><given-names>G</given-names></name><name><surname>Caruso</surname><given-names>C</given-names></name><name><surname>Jin</surname><given-names>K</given-names></name><name><surname>Zhao</surname><given-names>RC</given-names></name></person-group><article-title>Transplantation of ACE2-mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia</article-title><source>Aging Dis</source><year>2020</year><volume>11</volume><issue>2</issue><fpage>216</fpage><lpage>228</lpage><?supplied-pmid 32257537?><pub-id pub-id-type="pmid">32257537</pub-id></element-citation></ref><ref id="CR66"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shetty</surname><given-names>AK</given-names></name></person-group><article-title>Mesenchymal stem cell infusion shows promise for combating coronavirus (COVID-19)-induced pneumonia</article-title><source>Aging Dis</source><year>2020</year><volume>11</volume><issue>2</issue><fpage>462</fpage><lpage>464</lpage><?supplied-pmid 32257554?><pub-id pub-id-type="pmid">32257554</pub-id></element-citation></ref><ref id="CR67"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Foronjy</surname><given-names>RF</given-names></name><name><surname>Dabo</surname><given-names>AJ</given-names></name><name><surname>Cummins</surname><given-names>N</given-names></name><name><surname>Geraghty</surname><given-names>P</given-names></name></person-group><article-title>Leukemia inhibitory factor protects the lung during respiratory syncytial viral infection</article-title><source>BMC Immunol</source><year>2014</year><volume>15</volume><issue>1</issue><fpage>41</fpage><?supplied-pmid 25277705?><pub-id pub-id-type="pmid">25277705</pub-id></element-citation></ref><ref id="CR68"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Traber</surname><given-names>KE</given-names></name><etal/></person-group><article-title>Myeloid-epithelial cross talk coordinates synthesis of the tissue-protective cytokine leukemia inhibitory factor during pneumonia</article-title><source>Am J Phys Lung Cell Mol Phys</source><year>2017</year><volume>313</volume><issue>3</issue><fpage>L548</fpage><lpage>L558</lpage></element-citation></ref><ref id="CR69"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poon</surname><given-names>J</given-names></name><name><surname>Campos</surname><given-names>M</given-names></name><name><surname>Foronjy</surname><given-names>RF</given-names></name><name><surname>Nath</surname><given-names>S</given-names></name><name><surname>Gupta</surname><given-names>G</given-names></name><name><surname>Railwah</surname><given-names>C</given-names></name><name><surname>Dabo</surname><given-names>AJ</given-names></name><name><surname>Baumlin</surname><given-names>N</given-names></name><name><surname>Salathe</surname><given-names>M</given-names></name><name><surname>Geraghty</surname><given-names>P</given-names></name></person-group><article-title>Cigarette smoke exposure reduces leukemia inhibitory factor levels during respiratory syncytial viral infection</article-title><source>Int J Chronic Obstruct Pulmonary Dis</source><year>2019</year><volume>14</volume><fpage>1305</fpage><lpage>1315</lpage></element-citation></ref><ref id="CR70"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Metcalfe</surname><given-names>SM</given-names></name><etal/></person-group><article-title>Multiple sclerosis and the LIF/IL-6 axis: use of nanotechnology to harness the tolerogenic and reparative properties of LIF</article-title><source>Nanobiomedicine</source><year>2015</year><volume>2</volume><issue>Godi&#x00161;te 2015</issue><fpage>2</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">29942368</pub-id></element-citation></ref><ref id="CR71"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Manipulation of macrophage polarization by peptide-coated gold nanoparticles and its protective effects on acute lung injury</article-title><source>J Nanobiotechnol</source><year>2020</year><volume>18</volume><issue>1</issue><fpage>1</fpage><lpage>16</lpage></element-citation></ref><ref id="CR72"><label>72.</label><mixed-citation publication-type="other">Tolouian R et al (2020) COVID-19 interactions with angiotensin-converting enzyme 2 (ACE2) and the kinin system; looking at a potential treatment. J Renal Injury Prevent 9(2)</mixed-citation></ref><ref id="CR73"><label>73.</label><mixed-citation publication-type="other">Cheng H, Wang Y, Wang GQ (2020) Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19. J Med Virol</mixed-citation></ref><ref id="CR74"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoffmann</surname><given-names>M</given-names></name><name><surname>Kleine-Weber</surname><given-names>H</given-names></name><name><surname>Schroeder</surname><given-names>S</given-names></name><name><surname>Kr&#x000fc;ger</surname><given-names>N</given-names></name><name><surname>Herrler</surname><given-names>T</given-names></name><name><surname>Erichsen</surname><given-names>S</given-names></name><name><surname>Schiergens</surname><given-names>TS</given-names></name><name><surname>Herrler</surname><given-names>G</given-names></name><name><surname>Wu</surname><given-names>NH</given-names></name><name><surname>Nitsche</surname><given-names>A</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>MA</given-names></name><name><surname>Drosten</surname><given-names>C</given-names></name><name><surname>P&#x000f6;hlmann</surname><given-names>S</given-names></name></person-group><article-title>SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor</article-title><source>Cell</source><year>2020</year><volume>181</volume><fpage>271</fpage><lpage>280.e8</lpage><?supplied-pmid 7102627?><pub-id pub-id-type="pmid">32142651</pub-id></element-citation></ref><ref id="CR75"><label>75.</label><mixed-citation publication-type="other">Ju B et al (2020) Potent human neutralizing antibodies elicited by SARS-CoV-2 infection. bioRxiv</mixed-citation></ref><ref id="CR76"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Imai</surname><given-names>Y</given-names></name><name><surname>Kuba</surname><given-names>K</given-names></name><name><surname>Rao</surname><given-names>S</given-names></name><name><surname>Huan</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>F</given-names></name><name><surname>Guan</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>P</given-names></name><name><surname>Sarao</surname><given-names>R</given-names></name><name><surname>Wada</surname><given-names>T</given-names></name><name><surname>Leong-Poi</surname><given-names>H</given-names></name><name><surname>Crackower</surname><given-names>MA</given-names></name><name><surname>Fukamizu</surname><given-names>A</given-names></name><name><surname>Hui</surname><given-names>CC</given-names></name><name><surname>Hein</surname><given-names>L</given-names></name><name><surname>Uhlig</surname><given-names>S</given-names></name><name><surname>Slutsky</surname><given-names>AS</given-names></name><name><surname>Jiang</surname><given-names>C</given-names></name><name><surname>Penninger</surname><given-names>JM</given-names></name></person-group><article-title>Angiotensin-converting enzyme 2 protects from severe acute lung failure</article-title><source>Nature</source><year>2005</year><volume>436</volume><issue>7047</issue><fpage>112</fpage><lpage>116</lpage><?supplied-pmid 7094998?><pub-id pub-id-type="pmid">16001071</pub-id></element-citation></ref><ref id="CR77"><label>77.</label><mixed-citation publication-type="other">Zhang H et al (2020) Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med:1&#x02013;5</mixed-citation></ref><ref id="CR78"><label>78.</label><mixed-citation publication-type="other">Monteil V (2020) Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-grade soluble human ACE2. cellpress</mixed-citation></ref><ref id="CR79"><label>79.</label><mixed-citation publication-type="other">Lukassen S et al (2020) SARS-CoV-2 receptor ACE2 and TMPRSS2 are predominantly expressed in a transient secretory cell type in subsegmental bronchial branches. bioRxiv</mixed-citation></ref><ref id="CR80"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Al-Tawfiq</surname><given-names>JA</given-names></name><name><surname>Al-Homoud</surname><given-names>AH</given-names></name><name><surname>Memish</surname><given-names>ZA</given-names></name></person-group><article-title>Remdesivir as a possible therapeutic option for the COVID-19</article-title><source>Travel Med Infect Dis</source><year>2020</year><volume>34</volume><fpage>101615</fpage><?supplied-pmid 32145386?><pub-id pub-id-type="pmid">32145386</pub-id></element-citation></ref><ref id="CR81"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheahan</surname><given-names>TP</given-names></name><etal/></person-group><article-title>Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV</article-title><source>Nat Commun</source><year>2020</year><volume>11</volume><issue>1</issue><fpage>019</fpage><lpage>13940</lpage></element-citation></ref><ref id="CR82"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Choy</surname><given-names>K-T</given-names></name><name><surname>Wong</surname><given-names>AYL</given-names></name><name><surname>Kaewpreedee</surname><given-names>P</given-names></name><name><surname>Sia</surname><given-names>SF</given-names></name><name><surname>Chen</surname><given-names>D</given-names></name><name><surname>Hui</surname><given-names>KPY</given-names></name><name><surname>Chu</surname><given-names>DKW</given-names></name><name><surname>Chan</surname><given-names>MCW</given-names></name><name><surname>Cheung</surname><given-names>PPH</given-names></name><name><surname>Huang</surname><given-names>X</given-names></name><name><surname>Peiris</surname><given-names>M</given-names></name><name><surname>Yen</surname><given-names>HL</given-names></name></person-group><article-title>Remdesivir, lopinavir, emetine, and homoharringtonine inhibit SARS-CoV-2 replication in vitro</article-title><source>Antivir Res</source><year>2020</year><volume>178</volume><fpage>104786</fpage><?supplied-pmid 32251767?><pub-id pub-id-type="pmid">32251767</pub-id></element-citation></ref><ref id="CR83"><label>83.</label><mixed-citation publication-type="other">Grein J, Ohmagari N, Shin D, Diaz G, Asperges E, Castagna A, Feldt T, Green G, Green ML, Lescure FX, Nicastri E, Oda R, Yo K, Quiros-Roldan E, Studemeister A, Redinski J, Ahmed S, Bernett J, Chelliah D, Chen D, Chihara S, Cohen SH, Cunningham J, D&#x02019;Arminio Monforte A, Ismail S, Kato H, Lapadula G, L&#x02019;Her E, Maeno T, Majumder S, Massari M, Mora-Rillo M, Mutoh Y, Nguyen D, Verweij E, Zoufaly A, Osinusi AO, DeZure A, Zhao Y, Zhong L, Chokkalingam A, Elboudwarej E, Telep L, Timbs L, Henne I, Sellers S, Cao H, Tan SK, Winterbourne L, Desai P, Mera R, Gaggar A, Myers RP, Brainard DM, Childs R, Flanigan T (2020) Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med</mixed-citation></ref><ref id="CR84"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holshue</surname><given-names>ML</given-names></name><name><surname>DeBolt</surname><given-names>C</given-names></name><name><surname>Lindquist</surname><given-names>S</given-names></name><name><surname>Lofy</surname><given-names>KH</given-names></name><name><surname>Wiesman</surname><given-names>J</given-names></name><name><surname>Bruce</surname><given-names>H</given-names></name><name><surname>Spitters</surname><given-names>C</given-names></name><name><surname>Ericson</surname><given-names>K</given-names></name><name><surname>Wilkerson</surname><given-names>S</given-names></name><name><surname>Tural</surname><given-names>A</given-names></name><name><surname>Diaz</surname><given-names>G</given-names></name><name><surname>Cohn</surname><given-names>A</given-names></name><name><surname>Fox</surname><given-names>L</given-names></name><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>Gerber</surname><given-names>SI</given-names></name><name><surname>Kim</surname><given-names>L</given-names></name><name><surname>Tong</surname><given-names>S</given-names></name><name><surname>Lu</surname><given-names>X</given-names></name><name><surname>Lindstrom</surname><given-names>S</given-names></name><name><surname>Pallansch</surname><given-names>MA</given-names></name><name><surname>Weldon</surname><given-names>WC</given-names></name><name><surname>Biggs</surname><given-names>HM</given-names></name><name><surname>Uyeki</surname><given-names>TM</given-names></name><name><surname>Pillai</surname><given-names>SK</given-names></name><collab>Washington State 2019-nCoV Case Investigation Team</collab></person-group><article-title>First case of 2019 novel coronavirus in the United States</article-title><source>N Engl J Med</source><year>2020</year><volume>382</volume><issue>10</issue><fpage>929</fpage><lpage>936</lpage><?supplied-pmid 32004427?><pub-id pub-id-type="pmid">32004427</pub-id></element-citation></ref><ref id="CR85"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>du</surname><given-names>G</given-names></name><name><surname>du</surname><given-names>R</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>Y</given-names></name><name><surname>Fu</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>L</given-names></name><name><surname>Cheng</surname><given-names>Z</given-names></name><name><surname>Lu</surname><given-names>Q</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Luo</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>K</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>S</given-names></name><name><surname>Ruan</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>C</given-names></name><name><surname>Mei</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Ding</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>F</given-names></name><name><surname>Tang</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>X</given-names></name><name><surname>Ye</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>J</given-names></name><name><surname>Yin</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Fan</surname><given-names>G</given-names></name><name><surname>Zhou</surname><given-names>F</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Gu</surname><given-names>X</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Shang</surname><given-names>L</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Guo</surname><given-names>T</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Qin</surname><given-names>H</given-names></name><name><surname>Jiang</surname><given-names>Y</given-names></name><name><surname>Jaki</surname><given-names>T</given-names></name><name><surname>Hayden</surname><given-names>FG</given-names></name><name><surname>Horby</surname><given-names>PW</given-names></name><name><surname>Cao</surname><given-names>B</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name></person-group><article-title>Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial</article-title><source>Lancet</source><year>2020</year><volume>395</volume><fpage>1569</fpage><lpage>1578</lpage><?supplied-pmid 32423584?><pub-id pub-id-type="pmid">32423584</pub-id></element-citation></ref><ref id="CR86"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguiar</surname><given-names>AC</given-names></name><etal/></person-group><article-title>Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity</article-title><source>Int J Parasitol Drugs Drug Resist</source><year>2018</year><volume>8</volume><issue>3</issue><fpage>459</fpage><lpage>464</lpage><?supplied-pmid 30396013?><pub-id pub-id-type="pmid">30396013</pub-id></element-citation></ref><ref id="CR87"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cortegiani</surname><given-names>A</given-names></name><name><surname>Ingoglia</surname><given-names>G</given-names></name><name><surname>Ippolito</surname><given-names>M</given-names></name><name><surname>Giarratano</surname><given-names>A</given-names></name><name><surname>Einav</surname><given-names>S</given-names></name></person-group><article-title>A systematic review on the efficacy and safety of chloroquine for the treatment of COVID-19</article-title><source>J Crit Care</source><year>2020</year><volume>57</volume><fpage>279</fpage><lpage>283</lpage><?supplied-pmid 32173110?><pub-id pub-id-type="pmid">32173110</pub-id></element-citation></ref><ref id="CR88"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vincent</surname><given-names>MJ</given-names></name><etal/></person-group><article-title>Chloroquine is a potent inhibitor of SARS coronavirus infection and spread</article-title><source>Virol J</source><year>2005</year><volume>2</volume><issue>69</issue><fpage>2</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">15634356</pub-id></element-citation></ref><ref id="CR89"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golden</surname><given-names>EB</given-names></name><name><surname>Cho</surname><given-names>HY</given-names></name><name><surname>Hofman</surname><given-names>FM</given-names></name><name><surname>Louie</surname><given-names>SG</given-names></name><name><surname>Sch&#x000f6;nthal</surname><given-names>AH</given-names></name><name><surname>Chen</surname><given-names>TC</given-names></name></person-group><article-title>Quinoline-based antimalarial drugs: a novel class of autophagy inhibitors</article-title><source>Neurosurg Focus</source><year>2015</year><volume>38</volume><issue>3</issue><fpage>E12</fpage><?supplied-pmid 25727221?><pub-id pub-id-type="pmid">25727221</pub-id></element-citation></ref><ref id="CR90"><label>90.</label><mixed-citation publication-type="other">Chen Z et al (2020) Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv</mixed-citation></ref><ref id="CR91"><label>91.</label><mixed-citation publication-type="other">Gautret P, Lagier JC, Parola P, Hoang VT, Meddeb L, Mailhe M, Doudier B, Courjon J, Giordanengo V, Vieira VE, Dupont HT, Honor&#x000e9; S, Colson P, Chabri&#x000e8;re E, la Scola B, Rolain JM, Brouqui P, Raoult D (2020) Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents:105949</mixed-citation></ref><ref id="CR92"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Borba</surname><given-names>MGS</given-names></name><name><surname>Val</surname><given-names>FFA</given-names></name><name><surname>Sampaio</surname><given-names>VS</given-names></name><name><surname>Alexandre</surname><given-names>MAA</given-names></name><name><surname>Melo</surname><given-names>GC</given-names></name><name><surname>Brito</surname><given-names>M</given-names></name><name><surname>Mour&#x000e3;o</surname><given-names>MPG</given-names></name><name><surname>Brito-Sousa</surname><given-names>JD</given-names></name><name><surname>Ba&#x000ed;a-da-Silva</surname><given-names>D</given-names></name><name><surname>Guerra</surname><given-names>MVF</given-names></name><name><surname>Hajjar</surname><given-names>LA</given-names></name><name><surname>Pinto</surname><given-names>RC</given-names></name><name><surname>Balieiro</surname><given-names>AAS</given-names></name><name><surname>Pacheco</surname><given-names>AGF</given-names></name><name><surname>Santos</surname><given-names>JDO</given-names><suffix>Jr</suffix></name><name><surname>Naveca</surname><given-names>FG</given-names></name><name><surname>Xavier</surname><given-names>MS</given-names></name><name><surname>Siqueira</surname><given-names>AM</given-names></name><name><surname>Schwarzbold</surname><given-names>A</given-names></name><name><surname>Croda</surname><given-names>J</given-names></name><name><surname>Nogueira</surname><given-names>ML</given-names></name><name><surname>Romero</surname><given-names>GAS</given-names></name><name><surname>Bassat</surname><given-names>Q</given-names></name><name><surname>Fontes</surname><given-names>CJ</given-names></name><name><surname>Albuquerque</surname><given-names>BC</given-names></name><name><surname>Daniel-Ribeiro</surname><given-names>CT</given-names></name><name><surname>Monteiro</surname><given-names>WM</given-names></name><name><surname>Lacerda</surname><given-names>MVG</given-names></name><collab>for the CloroCovid-19 Team</collab></person-group><article-title>Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial</article-title><source>JAMA Netw Open</source><year>2020</year><volume>3</volume><issue>4</issue><fpage>e208857</fpage><lpage>e208857</lpage><?supplied-pmid 32339248?><pub-id pub-id-type="pmid">32339248</pub-id></element-citation></ref><ref id="CR93"><label>93.</label><mixed-citation publication-type="other">Jakhar D, Kaur I (2020) Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus. Nat Med:1&#x02013;1</mixed-citation></ref><ref id="CR94"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cvetkovic</surname><given-names>RS</given-names></name><name><surname>Goa</surname><given-names>KL</given-names></name></person-group><article-title>Lopinavir/ritonavir: a review of its use in the management of HIV infection</article-title><source>Drugs</source><year>2003</year><volume>63</volume><issue>8</issue><fpage>769</fpage><lpage>802</lpage><?supplied-pmid 12662125?><pub-id pub-id-type="pmid">12662125</pub-id></element-citation></ref><ref id="CR95"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arabi</surname><given-names>YM</given-names></name><etal/></person-group><article-title>Treatment of Middle East respiratory syndrome with a combination of lopinavir-ritonavir and interferon-&#x003b2;1b (MIRACLE trial): study protocol for a randomized controlled trial</article-title><source>Trials</source><year>2018</year><volume>19</volume><issue>1</issue><fpage>81</fpage><?supplied-pmid 29382391?><pub-id pub-id-type="pmid">29382391</pub-id></element-citation></ref><ref id="CR96"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>VC</given-names></name><name><surname>Hung</surname><given-names>IF</given-names></name><name><surname>Wong</surname><given-names>MM</given-names></name><name><surname>Chan</surname><given-names>KH</given-names></name><name><surname>Chan</surname><given-names>KS</given-names></name><name><surname>Kao</surname><given-names>RY</given-names></name><name><surname>Poon</surname><given-names>LL</given-names></name><name><surname>Wong</surname><given-names>CL</given-names></name><name><surname>Guan</surname><given-names>Y</given-names></name><name><surname>Peiris</surname><given-names>JS</given-names></name><name><surname>Yuen</surname><given-names>KY</given-names></name><collab>HKU/UCH SARS Study Group</collab></person-group><article-title>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings</article-title><source>Thorax</source><year>2004</year><volume>59</volume><issue>3</issue><fpage>252</fpage><lpage>256</lpage><?supplied-pmid 14985565?><pub-id pub-id-type="pmid">14985565</pub-id></element-citation></ref><ref id="CR97"><label>97.</label><mixed-citation publication-type="other">Lim J et al (2020) Case of the index patient who caused tertiary transmission of COVID-19 infection in Korea: the application of lopinavir/ritonavir for the treatment of COVID-19 infected pneumonia monitored by quantitative RT-PCR. J Korean Med Sci 35(6)</mixed-citation></ref><ref id="CR98"><label>98.</label><mixed-citation publication-type="other">Wu C et al (2020) Analysis of therapeutic targets for SARS-CoV-2 and discovery of potential drugs by computational methods. Acta Pharm Sin B</mixed-citation></ref><ref id="CR99"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Delang</surname><given-names>L</given-names></name><name><surname>Abdelnabi</surname><given-names>R</given-names></name><name><surname>Neyts</surname><given-names>J</given-names></name></person-group><article-title>Favipiravir as a potential countermeasure against neglected and emerging RNA viruses</article-title><source>Antivir Res</source><year>2018</year><volume>153</volume><fpage>85</fpage><lpage>94</lpage><?supplied-pmid 29524445?><pub-id pub-id-type="pmid">29524445</pub-id></element-citation></ref><ref id="CR100"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furuta</surname><given-names>Y</given-names></name><name><surname>Komeno</surname><given-names>T</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name></person-group><article-title>Favipiravir (T-705), a broad spectrum inhibitor of viral RNA polymerase</article-title><source>Proc Jpn Acad Series B</source><year>2017</year><volume>93</volume><issue>7</issue><fpage>449</fpage><lpage>463</lpage></element-citation></ref><ref id="CR101"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>L</given-names></name><name><surname>Hu</surname><given-names>S</given-names></name><name><surname>Gao</surname><given-names>J</given-names></name></person-group><article-title>Discovering drugs to treat coronavirus disease 2019 (COVID-19)</article-title><source>Drug Discov Ther</source><year>2020</year><volume>14</volume><issue>1</issue><fpage>58</fpage><lpage>60</lpage><?supplied-pmid 32147628?><pub-id pub-id-type="pmid">32147628</pub-id></element-citation></ref><ref id="CR102"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goodridge</surname><given-names>HS</given-names></name><name><surname>Ahmed</surname><given-names>SS</given-names></name><name><surname>Curtis</surname><given-names>N</given-names></name><name><surname>Kollmann</surname><given-names>TR</given-names></name><name><surname>Levy</surname><given-names>O</given-names></name><name><surname>Netea</surname><given-names>MG</given-names></name><name><surname>Pollard</surname><given-names>AJ</given-names></name><name><surname>van Crevel</surname><given-names>R</given-names></name><name><surname>Wilson</surname><given-names>CB</given-names></name></person-group><article-title>Harnessing the beneficial heterologous effects of vaccination</article-title><source>Nat Rev Immunol</source><year>2016</year><volume>16</volume><issue>6</issue><fpage>392</fpage><lpage>400</lpage><?supplied-pmid 27157064?><pub-id pub-id-type="pmid">27157064</pub-id></element-citation></ref><ref id="CR103"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arts</surname><given-names>RJ</given-names></name><etal/></person-group><article-title>BCG vaccination protects against experimental viral infection in humans through the induction of cytokines associated with trained immunity</article-title><source>Cell Host Microbe</source><year>2018</year><volume>23</volume><issue>1</issue><fpage>89</fpage><lpage>100. e5</lpage><?supplied-pmid 29324233?><pub-id pub-id-type="pmid">29324233</pub-id></element-citation></ref><ref id="CR104"><label>104.</label><mixed-citation publication-type="other">Miller A et al (2020) Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: an epidemiological study. medRxiv</mixed-citation></ref><ref id="CR105"><label>105.</label><mixed-citation publication-type="other">Dayal D, Gupta S (2020) Connecting BCG vaccination and COVID-19: additional data. medRxiv</mixed-citation></ref><ref id="CR106"><label>106.</label><mixed-citation publication-type="other">Organization WH Bacille Calmette-Gu&#x000e9;rin (BCG) vaccination and COVID-19: scientific brief, 12 April 2020. 2020, World Health Organization</mixed-citation></ref><ref id="CR107"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thompson</surname><given-names>BT</given-names></name></person-group><article-title>Glucocorticoids and acute lung injury</article-title><source>Crit Care Med</source><year>2003</year><volume>31</volume><issue>4</issue><fpage>S253</fpage><lpage>S257</lpage><?supplied-pmid 12682449?><pub-id pub-id-type="pmid">12682449</pub-id></element-citation></ref><ref id="CR108"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rhen</surname><given-names>T</given-names></name><name><surname>Cidlowski</surname><given-names>JA</given-names></name></person-group><article-title>Antiinflammatory action of glucocorticoids&#x02014;new mechanisms for old drugs</article-title><source>N Engl J Med</source><year>2005</year><volume>353</volume><issue>16</issue><fpage>1711</fpage><lpage>1723</lpage><?supplied-pmid 16236742?><pub-id pub-id-type="pmid">16236742</pub-id></element-citation></ref><ref id="CR109"><label>109.</label><mixed-citation publication-type="other">Yang X et al (2020) Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med</mixed-citation></ref><ref id="CR110"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Siddiqi</surname><given-names>HK</given-names></name><name><surname>Mehra</surname><given-names>MR</given-names></name></person-group><article-title>COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal</article-title><source>J Heart Lung Transplant</source><year>2020</year><volume>39</volume><fpage>405</fpage><lpage>407</lpage><?supplied-pmid 32362390?><pub-id pub-id-type="pmid">32362390</pub-id></element-citation></ref><ref id="CR111"><label>111.</label><mixed-citation publication-type="other">Wang Y et al (2020) Early, low-dose and short-term application of corticosteroid treatment in patients with severe COVID-19 pneumonia: single-center experience from Wuhan, China. medRxiv</mixed-citation></ref></ref-list></back></article>